[{"text": "Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference ACCESS Newswire \u00b7 Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Wed, Jan 8, 2025, 2:00 PM 4 min read In This Article: AMPH -4.24% RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 th , 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 30 days following the presentation. About Amphastar: Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com . The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST \u00ae , Amphadase \u00ae , Cortrosyn \u00ae , REXTOVY \u00ae and BAQSIMI \u00ae are the property of Amphastar Pharmaceuticals, Inc. Forward-Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI \u00ae , including its potential for continued revenue growth, the success of our integration of BAQSIMI \u00ae , the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as \"may,\" \"might,\" \"will,\" \"could,\" \"would,\" \"should,\" \"anticipate,\" \"predict,\" \"potential,\" \"continue,\" \"expect,\" \"intend,\" \"plan,\" \"project,\" \"believe,\" \"estimate,\" and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST \u00ae or that we will continue to experience significant sales of BAQSIMI \u00ae . You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Story Continues CONTACT: Bill Peters Chief Financial Officer (909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2025-01-08T11:00:00+00:00", "sentiment": {"score": 0.023755837231874466, "confidence": 0.03776337951421738, "probabilities": {"positive": 0.03776337951421738, "negative": 0.01400754228234291, "neutral": 0.9482290744781494}}, "embedding": [-0.09958819299936295, -0.07779578119516373, -0.030192850157618523, -0.11285895109176636, -0.11502598971128464, -0.002184150042012334, 0.0398922860622406, 0.13069579005241394, 0.07165080308914185, 0.02827645093202591, -0.033727601170539856, 0.08353619277477264, 0.11234456300735474, 0.07516901940107346, -0.05987364053726196, 0.003036217298358679, 0.055955253541469574, 0.052973587065935135, -0.11865037679672241, 0.02136959135532379, 0.10640710592269897, 0.10656145215034485, 0.04926493018865585, 0.01873408444225788, -0.03603807091712952, 0.0833219513297081, -0.1176333799958229, 0.00641615828499198, -0.1038065031170845, -0.05357133969664574, -0.04380065202713013, 0.09266722202301025, 0.02205146849155426, -0.11792459338903427, 0.11805345863103867, 0.144822359085083, -0.08729808777570724, 0.08382809162139893, 0.025517884641885757, 0.024092715233564377, 0.058583036065101624, -0.10720878094434738, -0.12748882174491882, -0.022617250680923462, 0.06596510857343674, -0.10387837886810303, -0.04283260926604271, 0.00032130535691976547, -0.03321194648742676, 0.16824515163898468, -0.13053855299949646, -0.1251135915517807, 0.07365266233682632, 0.09373122453689575, -0.04968934878706932, -0.07573937624692917, -0.1559656858444214, -0.03774993121623993, -0.019703280180692673, -0.007577791810035706, -0.061641842126846313, -0.03269309550523758, 0.010972612537443638, 0.021176541224122047, 0.09721547365188599, 0.061020560562610626, 0.10844030231237411, -0.09706299006938934, -0.040053535252809525, -0.028190869837999344, 0.07186306267976761, -0.11828873306512833, -0.005740785505622625, 0.2292570322751999, -0.11563730984926224, 0.1830158233642578, 0.2375246286392212, 0.04378679394721985, 0.08544312417507172, -0.11980967223644257, 0.07235583662986755, 0.12828998267650604, -0.053209539502859116, -0.01993756741285324, -0.06352311372756958, 0.025897739455103874, -0.005037182476371527, 0.09851999580860138, 0.01995149441063404, -0.0631096214056015, -0.0027302633970975876, -0.028675230219960213, 0.01890634186565876, -0.06884720921516418, 0.0027589183300733566, -0.13436032831668854, -0.11418841779232025, 0.05406295880675316, 0.11288443207740784, -0.010466419160366058, -0.010527513921260834, -0.005034288391470909, -0.09078116714954376, -0.07160202413797379, -0.013934673741459846, -0.11641092598438263, 0.014823798090219498, 0.05294833704829216, 0.08679895102977753, 0.0323643758893013, -0.08529618382453918, 0.12466247379779816, 0.007635884918272495, -0.06231670081615448, -0.07576446980237961, 0.21690183877944946, -0.05743259936571121, 0.04502551257610321, 0.19768714904785156, -0.11695423722267151, -0.01902451366186142, -0.03553246334195137, -0.014123001135885715, -0.15361842513084412, -0.012739167548716068, 0.05434371158480644, -0.1810685247182846, 6.629990911413218e-33, -0.03128981590270996, 0.05690629780292511, 0.08500173687934875, -0.012441011145710945, 0.020444603636860847, 0.023387711495161057, 0.023987097665667534, 0.03737812116742134, -0.10675451904535294, -0.05728008598089218, -0.12242777645587921, 0.17015624046325684, 0.001954304054379463, 0.0705089420080185, -0.14920449256896973, -0.05984171852469444, -0.021947264671325684, 0.03349463641643524, 0.018815666437149048, -0.15788230299949646, -0.07993672043085098, 0.05484222248196602, -0.056775763630867004, 0.16894277930259705, -0.0628841444849968, -0.027813751250505447, -0.04685664176940918, 0.07084590196609497, -0.0286654494702816, 0.0684998482465744, 0.02672887034714222, 0.07961449772119522, 0.025155868381261826, -0.15584954619407654, -0.10300000011920929, -0.12593978643417358, -0.10972881317138672, -0.16236792504787445, 0.0995045006275177, 0.02642565593123436, -0.03738666698336601, 0.019326087087392807, -0.16113007068634033, 0.058049529790878296, 0.01886928826570511, -0.05202040448784828, -0.10728008300065994, 0.04554601013660431, 0.12402691692113876, -0.0635596513748169, -0.06210002303123474, 0.03289346396923065, 0.025587748736143112, -0.08098739385604858, -0.027538293972611427, 0.03837081789970398, -0.165837824344635, -0.10475347936153412, 0.06153883785009384, 0.1577637493610382, -0.05576604977250099, 0.10430154204368591, -0.09163525700569153, 0.02626710943877697, -0.1142101138830185, 0.000489494763314724, 0.054415903985500336, -0.009422560222446918, -0.00806473009288311, 0.02585245668888092, 0.0803757756948471, -0.025866612792015076, 0.053000129759311676, -0.012749234214425087, 0.12862209975719452, -0.10370108485221863, 0.04684809595346451, 0.1367122381925583, -0.011735696345567703, 0.039869096130132675, -0.028590936213731766, 0.07536685466766357, -0.0624297559261322, 0.08216751366853714, -0.0825047492980957, 0.024470582604408264, 0.11949051916599274, -0.0333452969789505, -0.14376579225063324, -0.11084277927875519, -0.03348424658179283, -0.0034138262271881104, -0.1358994096517563, 0.15258705615997314, -0.019134849309921265, -8.366587654133355e-33, 0.10599379986524582, -0.023010361939668655, -0.00937232468277216, -0.03891158103942871, 0.001430615782737732, -0.004717933014035225, 0.21698351204395294, -0.052741728723049164, 0.027931250631809235, -0.10454826056957245, 0.08902961760759354, 0.05141647160053253, -0.06157679483294487, -0.04283184930682182, -0.10375270247459412, 0.07251088321208954, 0.02398846298456192, -0.03219186142086983, -0.024348683655261993, 0.09484073519706726, 0.04565194249153137, 0.16767029464244843, -0.07812471687793732, 0.05598284304141998, 0.03374800831079483, -0.0026344461366534233, 0.045649413019418716, 0.057132598012685776, 0.03681790828704834, 0.0421852208673954, -0.10921584069728851, 0.059431303292512894, -0.22629307210445404, 0.0018991564866155386, -0.009125923737883568, -0.06988853216171265, 0.05109471455216408, -0.1891976296901703, -0.037669502198696136, -0.10147597640752792, -0.004961023107171059, 0.03456587716937065, 0.0257895328104496, 0.05337201803922653, 0.1250607967376709, -0.011526847258210182, 0.09497212618589401, -0.08737185597419739, 0.04152654483914375, 0.03573521226644516, -0.020683102309703827, 0.0430387519299984, -0.005885974504053593, 0.028321977704763412, -0.11728433519601822, 0.04203188046813011, -0.02521730214357376, 0.012434782460331917, -0.07488606870174408, 0.017032476142048836, 0.08860855549573898, 0.050602756440639496, 0.04299435764551163, -0.09679996967315674, 0.007180072367191315, 0.06383991241455078, 0.10782712697982788, -0.08298546075820923, 0.16758780181407928, -0.13515347242355347, -0.02835613489151001, -0.08961912989616394, 0.002170010469853878, -0.12409675121307373, -0.14516691863536835, 0.05773213878273964, -0.0421002097427845, -0.08929364383220673, -0.16007071733474731, -0.03883843123912811, 0.10536141693592072, 0.06997708976268768, -0.039055898785591125, 0.14976933598518372, -0.010500846430659294, 0.05430539697408676, 0.020341169089078903, 0.016651922836899757, -0.05516238510608673, 0.11147279292345047, -0.12256108224391937, -0.11465369910001755, -0.1308351457118988, 0.1889425665140152, 0.016235854476690292, -1.0063617139621783e-07, 0.11242212355136871, 0.010748006403446198, 0.03225142881274223, 0.0029992740601301193, 0.10747185349464417, 0.008735723793506622, -0.048242729157209396, -0.01503870077431202, 0.0729440376162529, 0.14562544226646423, 0.0503498874604702, 0.12774130702018738, -0.09979680925607681, 0.035666678100824356, -0.07619498670101166, 0.013608171604573727, -0.10636842250823975, 0.07502783834934235, -0.04986071586608887, 0.006904354318976402, -0.17725282907485962, 0.0886063426733017, 0.017876433208584785, -0.03577013686299324, -0.01784394681453705, -0.061720993369817734, 0.05808950588107109, -0.09217138588428497, -0.01882297918200493, -0.037620529532432556, -0.049856238067150116, 0.05699750781059265, 0.10268957912921906, -0.027859002351760864, -0.006512068212032318, -0.11712683737277985, 0.07542294263839722, 0.07363071292638779, 0.039209213107824326, 0.07522310316562653, -0.026014450937509537, -0.053225912153720856, 0.036899957805871964, 0.11066783964633942, 0.010094506666064262, -0.04530462622642517, -0.16808637976646423, 0.06931747496128082, -0.030359255149960518, 0.021904196590185165, 0.1050596833229065, -0.0742911696434021, -0.0101316524669528, -0.13647329807281494, -0.041733331978321075, 0.03469491004943848, -0.11477266997098923, -0.11879287660121918, 0.051560159772634506, 0.03278213366866112, 0.12779219448566437, -0.0898151695728302, 0.23140272498130798, -0.02513887919485569], "changes": {"1wk": 5.050500737581015}}, {"text": "New Strong Sell Stocks for January 2nd Zacks Equity Research Thu, Jan 2, 2025, 1:42 PM 1 min read In This Article: AGCO -3.52% ASC -1.68% Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today: AGCO Corporation AGCO is an agricultural equipment manufacturing company. The Zacks Consensus Estimate for its current year earnings has been revised nearly 7% downward over the last 60 days. Amphastar Pharmaceuticals, Inc. AMPH is a bio-pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 2.7% downward over the last 60 days. Ardmore Shipping Corporation ASC is a company that engages in the seaborne transportation of petroleum products and chemicals. The Zacks Consensus Estimate for its current year earnings has been revised 5.4% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AGCO Corporation (AGCO) : Free Stock Analysis Report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Ardmore Shipping Corporation (ASC) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2025-01-02T10:42:00+00:00", "sentiment": {"score": -0.3776298984885216, "confidence": 0.40481677651405334, "probabilities": {"positive": 0.02718687802553177, "negative": 0.40481677651405334, "neutral": 0.5679963231086731}}, "embedding": [-0.23706524074077606, -0.2443651556968689, -0.09712132811546326, 0.09351396560668945, 0.01758916676044464, -0.12860099971294403, 0.020584579557180405, 0.0891014039516449, -0.11509533226490021, 0.09683691710233688, -0.014788561500608921, 0.20324206352233887, -0.06611871719360352, 0.02165241912007332, -0.17196951806545258, 0.023371711373329163, 0.2570546865463257, -0.14981688559055328, -0.11280282586812973, -0.015423702076077461, -0.08302362263202667, 0.009010745212435722, 0.06807367503643036, -0.07976734638214111, 0.14150962233543396, 0.024128546938300133, -0.18879137933254242, 0.0190278347581625, -0.1459731161594391, -0.22628042101860046, -0.12448517233133316, -0.018147896975278854, 0.1868775337934494, 0.0008391765877604485, 0.01795189641416073, 0.07076267153024673, -0.012882128357887268, 0.01759205013513565, 0.17641682922840118, -0.10303443670272827, 0.009994810447096825, -0.04986746981739998, -0.05599220469594002, -0.09946280717849731, -0.14320072531700134, -0.1583983153104782, -0.052621688693761826, -0.11436469852924347, 0.1584320217370987, 0.0894591361284256, 0.027461595833301544, -0.09420553594827652, 0.03476608172059059, 0.03546091541647911, -0.16342449188232422, -0.0017274306155741215, -0.3005620241165161, -0.1324901282787323, 0.01175148319453001, 0.0338158942759037, 0.14104776084423065, 0.03792676329612732, -0.06000601872801781, 0.02117192931473255, 0.04439939931035042, -0.05473652482032776, 0.08274389803409576, 0.07952659577131271, -0.04716940596699715, 0.047185976058244705, 0.11229928582906723, -0.05244782939553261, 0.04380432516336441, 0.02580658346414566, 0.006437981501221657, 0.10912378132343292, 0.08733324706554413, -0.03367681801319122, 0.19911512732505798, -0.09503708779811859, 0.06036192551255226, 0.05516635999083519, -0.1139521598815918, -0.04157853126525879, -0.12806129455566406, 0.04890214651823044, 0.1442604809999466, 0.11877218633890152, -0.04072229564189911, 0.010728380642831326, 0.18018479645252228, -0.000282730208709836, 0.07220662385225296, -0.08070682734251022, 0.04103303700685501, -0.03708331659436226, -0.026936810463666916, 0.12786860764026642, -0.04715040698647499, -0.0006756428047083318, 0.11728212237358093, 0.2774554491043091, -0.01017672661691904, -0.14143243432044983, 0.018616212531924248, -0.1808396726846695, 0.013316121883690357, 0.007840721867978573, 0.03489493206143379, 0.10586588084697723, -0.05493912100791931, 0.17697808146476746, -0.16166481375694275, -0.005599139723926783, -0.27957257628440857, 0.14570924639701843, -0.09732472151517868, -0.006296530831605196, 0.044236402958631516, -0.0539405457675457, 0.007055182009935379, 0.07878918200731277, 0.02095004916191101, 0.03803347796201706, 0.13669165968894958, 0.0599634014070034, -0.1430942714214325, 1.0971486074291421e-32, -0.019572243094444275, 0.11910088360309601, 0.0654010996222496, -0.09623905271291733, -0.04709387943148613, 0.09175911545753479, -0.022429484874010086, 0.03184754028916359, -0.04002392664551735, -0.011906002648174763, -0.25398164987564087, 0.08224323391914368, 0.033096544444561005, 0.04388175904750824, -0.1115524172782898, -0.1735478937625885, 0.04732990637421608, -0.031521543860435486, 0.10789631307125092, -0.22320538759231567, -0.029848845675587654, -0.13452546298503876, -0.13315370678901672, -0.007111443672329187, 0.037383731454610825, -0.14398975670337677, -0.009345770813524723, 0.1664707213640213, -0.06984002143144608, 0.12165935337543488, 0.04262373596429825, 0.13014136254787445, -0.013855847530066967, 0.053074005991220474, -0.006283949129283428, -0.036085426807403564, -0.13789892196655273, -0.03334519639611244, 0.10063476115465164, -0.08052235841751099, -0.1457396000623703, 0.10688469558954239, -0.15401504933834076, 0.024377252906560898, -0.10159099847078323, 0.01641870103776455, -0.10291994363069534, 0.07559969276189804, 0.13818278908729553, 0.10717357695102692, -0.20249009132385254, -0.052172742784023285, -0.023082848638296127, 0.04240274801850319, 0.046195317059755325, 0.039712607860565186, -0.04798548296093941, -0.14019691944122314, 0.025432657450437546, 0.19997847080230713, 0.02328088879585266, 0.22642463445663452, -0.07810395210981369, -0.048220645636320114, -0.20299504697322845, 0.024192506447434425, -0.04139840230345726, 0.08511744439601898, -0.08896209299564362, 0.15572905540466309, 0.12761935591697693, -0.02537698484957218, 0.07512009143829346, -0.08873970806598663, 0.07672858238220215, 0.038179732859134674, 0.10497848689556122, 0.0658024325966835, 0.05470019951462746, 0.0012253780150786042, 0.06697266548871994, -0.0014508413150906563, 0.04412813484668732, 0.10715676099061966, -0.13266536593437195, 0.03936626389622688, 0.07103942334651947, 0.0012982640182599425, -0.08476323634386063, 0.030804766342043877, 0.0011590182548388839, -0.0513099767267704, -0.09966069459915161, 0.03724879026412964, -0.024129919707775116, -1.2178837056704962e-32, 0.18109586834907532, 0.03923714905977249, 0.018589599058032036, -0.0383734330534935, -0.07290074229240417, -0.03180747479200363, 0.24672366678714752, 0.15975815057754517, 0.034129370003938675, -0.01956309750676155, 0.09104835242033005, 0.20968012511730194, -0.01413344219326973, 0.019850559532642365, 0.02092016115784645, -0.07371410727500916, -0.012582666240632534, -0.11691968142986298, 0.13226693868637085, 0.05457725375890732, 0.008533766493201256, 0.076385498046875, -0.12468546628952026, 0.21490556001663208, -0.05026184022426605, -0.06896720081567764, -0.07148116081953049, 0.0181757640093565, -0.09780696779489517, 0.06590744853019714, 0.03616552799940109, 0.02489512972533703, -0.09215693920850754, 0.14033904671669006, -0.11611788719892502, -0.029286816716194153, 0.024519875645637512, -0.010424908250570297, -0.030684825032949448, -0.11317648738622665, 0.0377766452729702, 0.10523541271686554, -0.04398419335484505, -0.03816308081150055, 0.094721719622612, -0.024109045043587685, 0.11431825160980225, 0.05305919423699379, 0.18763232231140137, -0.06676707416772842, -0.06620089709758759, -0.026732642203569412, 0.04453504458069801, 0.11522004753351212, 0.00225461577065289, 0.1290850192308426, 0.0594288669526577, -0.028085695579648018, -0.3120957314968109, -0.05538048595190048, 0.006862435955554247, 0.152176633477211, 0.054279983043670654, 0.027512982487678528, -0.030773304402828217, 0.018061438575387, 0.08198576420545578, -0.04033322632312775, -0.00916955154389143, -0.08299858868122101, -0.04270380735397339, -0.16813406348228455, -0.027663320302963257, -0.1488177329301834, -0.1523381769657135, -0.0671166181564331, -0.036104317754507065, -0.04131091386079788, -0.17675678431987762, 0.01636553555727005, 0.14032188057899475, 0.13133692741394043, -0.0766916424036026, 0.12398757040500641, -0.0394737683236599, 0.14851011335849762, 0.07363808900117874, 0.02732747048139572, 0.01871674507856369, 0.16048835217952728, -0.1642637848854065, -0.11448236554861069, -0.19254225492477417, 0.19040773808956146, 0.06979761272668839, -9.976873371897454e-08, 0.047692667692899704, -0.04272523149847984, 0.10556694865226746, -0.005642871372401714, 0.11165353655815125, 0.016666797921061516, 0.010918811894953251, 0.07460188120603561, 0.029818972572684288, 0.13729849457740784, 0.02929239347577095, 0.04624859243631363, -0.31168678402900696, 0.009037722833454609, -0.09207741916179657, -0.012410148046910763, -0.026067521423101425, 0.14907275140285492, 0.007097797468304634, -0.1886579990386963, -0.10351306945085526, 0.08035532385110855, 0.1260853111743927, -0.01701321080327034, -0.021011067554354668, 0.01377626322209835, 0.0023370215203613043, -0.12443616986274719, -0.02808871865272522, 0.0302711334079504, 0.07841561734676361, 0.03955380246043205, 0.05702687427401543, -0.10168872028589249, 0.03715973719954491, -0.04451218247413635, 0.0067187342792749405, -0.0003113726561423391, 0.0550413653254509, 0.11124689877033234, -0.09975498914718628, 0.15380676090717316, -0.07086122035980225, 0.05072673410177231, 0.028424911201000214, -0.08255436271429062, -0.16112498939037323, -0.019897274672985077, 0.03741919621825218, -0.03868197277188301, 0.2490530014038086, -0.10129312425851822, -0.013328930363059044, 0.0046590291894972324, 0.07831475883722305, 0.023966670036315918, -0.2501913011074066, -0.15808793902397156, -0.06094672903418541, 0.1774546205997467, 0.05224335566163063, -0.2328721135854721, -0.022945955395698547, 0.14232346415519714], "changes": {"1wk": 0.7425755039366081, "1mo": -4.0979143384354035}}, {"text": "New Strong Sell Stocks for December 31st Zacks Equity Research Tue, Dec 31, 2024, 1:49 PM 1 min read In This Article: CR -0.59% Here are three stocks added to the Zacks Rank #24 (Strong Sell) List today: Agilon Health, Inc. AGL is a healthcare services company for seniors. The Zacks Consensus Estimate for its current year earnings has been revised 59% downward over the last 60 days. Amphastar Pharmaceuticals, Inc. AMPH is a bio-pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 3% downward over the last 60 days. Crane Company CR is an engineered industrial products company. The Zacks Consensus Estimate for its current year earnings has been revised 5.7% downward over the last 60 days. View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilon Health, Inc. (AGL) : Free Stock Analysis Report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Crane Company (CR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-12-31T10:49:00+00:00", "sentiment": {"score": -0.40420021302998066, "confidence": 0.4303748607635498, "probabilities": {"positive": 0.026174647733569145, "negative": 0.4303748607635498, "neutral": 0.5434504747390747}}, "embedding": [-0.2981712818145752, -0.0906117632985115, -0.00040346570312976837, 0.011485270224511623, -0.011354352347552776, -0.07603602111339569, -0.0726434737443924, 0.17822150886058807, 0.007711181417107582, 0.0480421707034111, -0.059787724167108536, 0.18652832508087158, 0.038215652108192444, 0.011932955123484135, -0.1288076788187027, 0.016142334789037704, 0.09114021062850952, -0.11277180910110474, -0.207209512591362, -0.044764403253793716, -0.12601767480373383, 0.000527461408637464, 0.11762139946222305, -0.028272248804569244, 0.1586383730173111, 0.014729619026184082, -0.19762390851974487, 0.12368172407150269, -0.020140917971730232, -0.1054212674498558, -0.04631292074918747, -0.06415679305791855, 0.21115338802337646, -0.02355743572115898, -0.04260418936610222, 0.11727934330701828, 0.01884695142507553, 0.006829213351011276, 0.1121399775147438, -0.030380703508853912, 0.07392405718564987, -0.003651874605566263, -0.09848397970199585, -0.1859317421913147, -0.0563187412917614, -0.16874456405639648, 0.011183150112628937, -0.13759106397628784, 0.11384935677051544, 0.14476308226585388, -0.1700090765953064, -0.1224287673830986, 0.13696326315402985, 0.05682646855711937, -0.13672390580177307, 0.04674689099192619, -0.17203278839588165, -0.15813545882701874, -0.006423645187169313, -0.01876145228743553, 0.14485876262187958, -0.01973641663789749, -0.04747212678194046, 0.02381482720375061, 0.028019271790981293, 0.05289702117443085, 0.028496334329247475, -0.007380958180874586, -0.002199010457843542, 0.04752920940518379, 0.08666159212589264, -0.10414237529039383, -0.02779403142631054, 0.0345354825258255, -0.024178212508559227, 0.06991177797317505, 0.09424374252557755, -0.08923663944005966, 0.13113205134868622, -0.10171040892601013, 0.009950116276741028, -0.04539751634001732, -0.055540040135383606, -0.046201322227716446, -0.04368932917714119, 0.08542146533727646, 0.09715308994054794, 0.08630301803350449, -0.03856677934527397, -0.009018675424158573, 0.09071997553110123, 0.06719967722892761, 0.013028305023908615, -0.003412024350836873, 0.03572791442275047, 0.04758920893073082, -0.10087075084447861, 0.0352286621928215, -0.12981614470481873, 0.10678739100694656, 0.07527288049459457, 0.22412405908107758, -0.018903197720646858, -0.08926184475421906, 0.018183859065175056, -0.16273272037506104, 0.061888713389635086, 0.10428920388221741, -0.11550802737474442, 0.037915315479040146, 0.05494493618607521, 0.10377370566129684, -0.03946024179458618, -0.0027856333181262016, -0.1222115010023117, 0.11989161372184753, -0.13461747765541077, 0.0661415234208107, 0.09275228530168533, 0.038124702870845795, 0.07796549052000046, 0.076034314930439, -0.0387941338121891, -0.04378381744027138, 0.1232590526342392, 0.035836078226566315, -0.21302255988121033, 1.3713550726195032e-32, 0.023427467793226242, 0.12098153680562973, 0.1262863725423813, -0.019852876663208008, -0.03521334379911423, 0.05172157287597656, -0.05311637371778488, 0.08473105728626251, -0.019501211121678352, -0.029074782505631447, -0.11148770898580551, 0.09309655427932739, 0.04926160350441933, -0.1226259395480156, -0.13247676193714142, -0.1247655525803566, 0.019527284428477287, -0.01619284227490425, 0.020144328474998474, -0.17305076122283936, 0.06932147592306137, -0.13922807574272156, -0.055386561900377274, -0.021312355995178223, 0.03788616880774498, -0.1330445408821106, 0.05566670745611191, 0.126923605799675, -0.10621313750743866, 0.08926395326852798, 0.025595057755708694, 0.04786238446831703, -0.03847964480519295, -0.027293020859360695, -0.03907455503940582, -0.06732650846242905, -0.11320264637470245, 0.00965255405753851, 0.06973055005073547, 0.09077548235654831, -0.005482271779328585, 0.07414013892412186, -0.1574876606464386, 0.005621621850878, 0.003319042269140482, 0.03625570237636566, -0.11689784377813339, 0.06664738804101944, 0.06269045919179916, 0.08635446429252625, -0.07955069094896317, -0.028074098750948906, -0.0017658071592450142, 0.043352287262678146, -0.06312365084886551, 0.04711303114891052, -0.06533778458833694, -0.1343385875225067, 0.039124228060245514, 0.15799501538276672, 0.04368763044476509, 0.13826200366020203, -0.02073267288506031, -0.1014079600572586, -0.14634136855602264, 0.03664850443601608, -0.04204068332910538, 0.05201049894094467, -0.08926242589950562, 0.21118542551994324, 0.15315891802310944, 0.039951615035533905, 0.03986450657248497, 0.006778007838875055, 0.0930316224694252, -0.06475994735956192, 0.04987094923853874, 0.04238736629486084, 0.03579920530319214, 0.09080992639064789, 0.10584180057048798, 0.06045868247747421, -0.027876093983650208, 0.0667838305234909, -0.09653294086456299, -0.06166883558034897, 0.019206278026103973, -0.08076128363609314, -0.023935696110129356, -0.041202396154403687, -0.03437379002571106, -0.08798811584711075, -0.053219493478536606, 0.04744507744908333, -0.13983553647994995, -1.2004269533452129e-32, 0.06367986649274826, 0.05290240794420242, -0.01176278293132782, -0.0028262061532586813, -0.011435914784669876, -0.056132972240448, 0.11855714023113251, 0.16342787444591522, 0.09158019721508026, 0.06681891530752182, 0.18273209035396576, 0.14438851177692413, -0.0041926149278879166, 0.07389013469219208, 0.05851617455482483, 0.025915173813700676, 0.0038067777641117573, -0.22003906965255737, 0.08091721683740616, 0.03316163271665573, 0.060583893209695816, 0.15777158737182617, -0.09309187531471252, 0.3246152997016907, 0.06715530157089233, 0.04238530248403549, -0.1326455920934677, 0.06749048829078674, 0.054903794080019, 0.03048509731888771, -0.026875998824834824, -0.04247790947556496, -0.05349582061171532, 0.14913122355937958, -0.1165177971124649, -0.011431928724050522, 0.01697421260178089, -0.11054153740406036, -0.0072249798104166985, -0.09106481075286865, 0.16558779776096344, 0.035049986094236374, -0.028826430439949036, -0.014167067594826221, 0.06290306150913239, 0.007956038229167461, 0.05222451314330101, 0.016471005976200104, 0.09510768949985504, -0.0752047747373581, -0.030074818059802055, 0.008108104579150677, -0.06115427240729332, 0.11270423233509064, -0.011516951024532318, 0.07201021909713745, 0.06352601945400238, 0.020114660263061523, -0.24323463439941406, -0.04254145547747612, 0.01810522750020027, 0.09878383576869965, -0.03700583800673485, 0.0740780234336853, -0.04211665689945221, 0.01887173019349575, 0.05693382769823074, -0.06510606408119202, -0.016135772690176964, -0.12447506189346313, 0.023174433037638664, -0.12835533916950226, 0.045410457998514175, -0.21731865406036377, -0.12324028462171555, 0.16248376667499542, -0.012802962213754654, -0.14016568660736084, -0.14195625483989716, -0.03224801644682884, 0.08308040350675583, 0.02365158498287201, 0.023107444867491722, 0.08656739443540573, -0.12708091735839844, 0.15181027352809906, -0.019797012209892273, -0.015316877514123917, -0.014963854104280472, 0.05262928083539009, -0.13112333416938782, -0.17032545804977417, -0.13580146431922913, 0.20477153360843658, 0.15885204076766968, -9.961832603266885e-08, 0.0914948582649231, 0.002770539140328765, 0.056970249861478806, 0.00677050556987524, 0.07073497772216797, -0.017708035185933113, 0.00846974179148674, -0.005773636978119612, 0.1164361983537674, 0.18581745028495789, -0.05274564027786255, -0.04572391137480736, -0.209927037358284, -0.016305504366755486, -0.15074807405471802, 0.00040983036160469055, -0.08502019196748734, 0.13964685797691345, 0.01425797026604414, -0.22801901400089264, -0.05879132077097893, 0.06408077478408813, 0.15861597657203674, 0.011557874269783497, 0.007687246892601252, -0.06385892629623413, -0.12764093279838562, -0.10386139899492264, -0.046700362116098404, -0.009523513726890087, 0.019399026408791542, 0.013905392959713936, 0.12698718905448914, -0.04430769011378288, 0.016624098643660545, -0.04024948179721832, 0.012182517908513546, 0.004647524561733007, -0.006143379025161266, 0.054471954703330994, 0.011010692454874516, 0.010920818895101547, -0.09044955670833588, 0.001615538029000163, -0.049501847475767136, -0.08593489229679108, -0.01108493935316801, -0.04215950891375542, 0.06032131239771843, -0.12811179459095, 0.25134170055389404, -0.08374150842428207, 0.0697285458445549, 0.009503889828920364, 0.007587511092424393, 0.09804581105709076, -0.17286653816699982, -0.141096293926239, -0.060028936713933945, 0.08572261780500412, 0.10375331342220306, -0.2100030481815338, -0.008624686859548092, 0.08464550971984863], "changes": {"1wk": -4.578509868127368, "1mo": -1.91220813020559}}, {"text": "Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 1:35 AM 3 min read In This Article: AMPH -4.24% Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -4.95%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.78 per share when it actually produced earnings of $0.94, delivering a surprise of 20.51%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Amphastar , which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $191.21 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 2.51%. This compares to year-ago revenues of $180.56 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Amphastar shares have lost about 16.6% since the beginning of the year versus the S&P 500's gain of 21.2%. What's Next for Amphastar? While Amphastar has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Amphastar: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.99 on $198.38 million in revenues for the coming quarter and $4.03 on $748.75 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Generic Drugs is currently in the top 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, BridgeBio Pharma (BBIO), is yet to report results for the quarter ended September 2024. This rare disease drug developer is expected to post quarterly loss of $1.03 per share in its upcoming report, which represents a year-over-year change of +4.6%. The consensus EPS estimate for the quarter has been revised 5.7% higher over the last 30 days to the current level. BridgeBio Pharma's revenues are expected to be $5.97 million, up 45.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-06T22:35:11+00:00", "sentiment": {"score": -0.6075781881809235, "confidence": 0.6807230710983276, "probabilities": {"positive": 0.07314488291740417, "negative": 0.6807230710983276, "neutral": 0.2461320161819458}}, "embedding": [-0.044167716056108475, 0.009827733039855957, 0.047776959836483, 0.03456879034638405, -0.08865880966186523, -0.0005573108792304993, -0.014360185712575912, 0.13095323741436005, 0.12864945828914642, 0.1613006740808487, -0.07251742482185364, 0.10988783836364746, 0.06551667302846909, -0.03647533431649208, -0.13773119449615479, 0.04634183272719383, 0.11949191987514496, -0.08527786284685135, -0.11587174981832504, 0.035944487899541855, 0.016552269458770752, 0.008595027029514313, 0.14855822920799255, -0.04022730141878128, 0.1479857861995697, 0.12776480615139008, -0.143987774848938, 0.09160736948251724, -0.12632867693901062, -0.20605042576789856, -0.02971712499856949, 0.07746677845716476, 0.0697261318564415, -0.07636663317680359, -0.10165418684482574, 0.012168834917247295, -0.04396820068359375, 0.14372633397579193, 0.14041785895824432, 0.06030113995075226, -0.03069980815052986, -0.0013275444507598877, -0.19620594382286072, -0.12157543748617172, -0.07529585063457489, -0.247390478849411, -0.04049748182296753, -0.031170103698968887, 0.01881570927798748, 0.12062937766313553, -0.08826819807291031, -0.14438006281852722, 0.15289631485939026, 0.08452378213405609, -0.08606106787919998, -0.02656102553009987, -0.1255255490541458, -0.01569325104355812, 0.10113309323787689, 0.08386668562889099, -0.03872174769639969, 0.03731389343738556, 0.01794419065117836, -0.0066210199147462845, 0.17916613817214966, -0.0261759702116251, 0.11992912739515305, 0.009199116379022598, -0.07925988733768463, 0.016473107039928436, 0.10468732565641403, 9.74766444414854e-05, -0.07532031834125519, -0.02602228708565235, -0.10752913355827332, 0.04614759981632233, 0.1766735315322876, 0.03262091428041458, 0.08120443671941757, -0.06082732975482941, 0.05419022589921951, -0.01570831798017025, -0.15447348356246948, -0.08116157352924347, 0.045808322727680206, -0.00916483998298645, 0.12299391627311707, 0.1322045624256134, 0.0019180264789611101, -0.01656775362789631, -0.03755974769592285, -0.037362970411777496, 0.005369536578655243, -0.09143737703561783, 0.11090689897537231, 0.0021146899089217186, -0.14101779460906982, -0.0363006666302681, 0.049751657992601395, 0.07862895727157593, 0.13473981618881226, 0.12946543097496033, -0.09150363504886627, -0.16900761425495148, 0.07205146551132202, -0.15225699543952942, 0.12501677870750427, 0.01758350245654583, -0.03213409334421158, 0.026434576138854027, -0.0047905948013067245, 0.07371938228607178, -0.13271969556808472, 0.020180905237793922, -0.0781448632478714, 0.12727046012878418, -0.01210133545100689, 0.1374512016773224, 0.05130325257778168, 0.04566437751054764, 0.0550210177898407, 0.007675159722566605, 0.03282484412193298, -0.021624945104122162, 0.006257584318518639, 0.1026441752910614, -0.23616090416908264, 7.80694801801831e-33, 0.10632067173719406, 0.11817418038845062, -0.00872994214296341, -0.11849990487098694, 0.0200175978243351, 0.03367266058921814, -0.011562332510948181, 0.0460241474211216, 0.003539007157087326, -0.1407068520784378, -0.1468416154384613, 0.13954657316207886, 0.022664286196231842, -0.05921868979930878, -0.06653669476509094, -0.13238312304019928, -0.03579375520348549, 0.04503805935382843, -0.015036344528198242, -0.07579067349433899, -0.06171545758843422, -0.10201364755630493, -0.07892044633626938, 0.06684044748544693, -0.04656350240111351, 0.02070952020585537, -0.01918686181306839, 0.0873466357588768, -0.15693435072898865, 0.04080531746149063, 0.014123502187430859, 0.09045162796974182, 0.03815766051411629, -0.16980557143688202, -0.09431515634059906, -0.12046735733747482, -0.021809620782732964, -0.06284181773662567, 0.15305563807487488, 0.006478382274508476, -0.09620315581560135, 0.06521949172019958, -0.16995869576931, -0.17206603288650513, -0.06727491319179535, 0.035318389534950256, -0.08185286074876785, 0.06966980546712875, 0.05134857818484306, 0.06567540764808655, -0.02193445898592472, 0.02259097807109356, -0.0028954893350601196, -0.06866711378097534, -0.11197412014007568, 0.05147685110569, -0.1346340775489807, -0.23748071491718292, 0.08634117990732193, 0.22111015021800995, 0.036011502146720886, 0.26533907651901245, 0.04429849982261658, -0.08022818714380264, -0.19845938682556152, 0.14195267856121063, 0.030291030183434486, 0.025759218260645866, -0.03689005970954895, 0.16556668281555176, 0.022161690518260002, -0.05950424075126648, 0.11342407017946243, -0.03432415425777435, 0.17503708600997925, -0.0419507771730423, 0.002197699621319771, 0.013126879930496216, 0.09770894050598145, 0.08591179549694061, 0.08006550371646881, -0.049154020845890045, -0.0016555455513298512, -0.012125836685299873, -0.07277645915746689, 0.029125213623046875, 0.11781062185764313, 0.01897481456398964, -0.00964475329965353, -0.0488467812538147, 0.010839871130883694, -0.09790129214525223, -0.12071549147367477, 0.05441925674676895, -0.05710899457335472, -8.20237182800745e-33, 0.08650550246238708, 0.11758420616388321, -0.0013222433626651764, -0.0014821626245975494, 0.012514611706137657, -0.01008976437151432, 0.19895517826080322, 0.10483846068382263, -0.017305411398410797, -0.040039148181676865, 0.04656413942575455, 0.03633718937635422, -0.10185028612613678, 0.03470585495233536, 0.028447115793824196, 0.037798166275024414, 0.06703449785709381, -0.19448497891426086, 0.12275435775518417, 0.00510321743786335, 0.0259366687387228, 0.1923418790102005, -0.07058108597993851, 0.2171623706817627, 0.03963708505034447, -0.003209321526810527, -0.04150181636214256, 0.12179164588451385, -0.06504086405038834, -0.014912491664290428, -0.042066819965839386, -0.058527737855911255, -0.1212361603975296, -0.04270847514271736, -0.0033437300007790327, -0.026684222742915154, -0.018093761056661606, -0.119206003844738, -0.00795435905456543, -0.04418289661407471, 0.10396943986415863, 0.0331144817173481, 0.0676182433962822, 0.02274293638765812, 0.10068962723016739, -0.03802851587533951, 0.07996426522731781, 0.013579240068793297, 0.1017720028758049, 0.028078969568014145, 0.03603563457727432, 0.05619208514690399, -0.04322998970746994, 0.10679331421852112, -0.1333838701248169, 0.040524259209632874, -0.13390520215034485, 0.059638556092977524, -0.14552761614322662, 0.03489825129508972, -0.03005409613251686, 0.1270831823348999, -0.0007876046001911163, -0.028018776327371597, -0.046248745173215866, -0.02676457166671753, 0.0636826753616333, -0.1534881889820099, 0.10351630300283432, -0.10894337296485901, -0.001068092416971922, -0.13835152983665466, 0.14429226517677307, -0.16051501035690308, -0.056942168623209, 0.1839888095855713, -0.04803731292486191, -0.1844739317893982, -0.12159174680709839, -0.04327293857932091, 0.08124645054340363, 0.16050828993320465, 0.020194213837385178, -0.02309275232255459, -0.11641129851341248, 0.1659487932920456, 0.015540163964033127, -0.0189574733376503, -0.05106089636683464, 0.043419789522886276, -0.11944394558668137, -0.18745824694633484, -0.19462788105010986, 0.10210424661636353, 0.10626307129859924, -1.0012276163706701e-07, 0.14829428493976593, -0.006584637798368931, 0.09693590551614761, 0.05497448146343231, 0.18613480031490326, 0.0003034621477127075, 0.020074965432286263, -0.06368449330329895, 0.11300477385520935, 0.1275554746389389, 0.07793700695037842, 0.054498083889484406, -0.22536100447177887, 0.005222133360803127, -0.12460571527481079, 0.04403986781835556, -0.06577485799789429, 0.14875666797161102, -0.03733094781637192, -0.11363248527050018, -0.09405352920293808, 0.09577400237321854, 0.048911966383457184, -0.1123734563589096, 0.11349579691886902, 0.0014312523417174816, -0.08891626447439194, -0.10235510021448135, -0.037733472883701324, -0.017452992498874664, 0.09154176712036133, 1.0795891284942627e-05, 0.04620102792978287, -0.004903917666524649, 0.03150501847267151, -0.10741682350635529, 0.06079358607530594, 0.11063794791698456, 0.029526840895414352, 0.07961998879909515, -0.02757715806365013, 0.013663598336279392, 0.037525370717048645, 0.05267399549484253, -0.11837310343980789, -0.145653635263443, -0.16653946042060852, -0.007393030449748039, -0.02736392617225647, -0.19399425387382507, 0.2171202003955841, -0.07672055065631866, 0.031525954604148865, -0.04487387090921402, 0.04485146701335907, 0.023974061012268066, -0.23790483176708221, -0.10519987344741821, -0.21433697640895844, -0.02367820218205452, 0.16994212567806244, -0.22222574055194855, 0.04265333339571953, 0.05897611007094383], "changes": {"1wk": -14.831463965041944, "1mo": -17.977531862365158}}, {"text": "Implied Volatility Surging for Amphastar Pharmceuticals (AMPH) Stock Options Zacks Equity Research Wed, Dec 4, 2024, 10:54 PM 2 min read In This Article: AMPH -4.24% Investors in Amphastar Pharmceuticals, Inc. AMPH need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $20.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Amphastar Pharmceuticals shares, but what is the fundamental picture for the company? Currently, Amphastar Pharmceuticals is a Zacks Rank #4 (Sell) in the\u00a0Medical-Generic Drugs industry that ranks in the Top 22% of our Zacks Industry Rank. Over the last 60 days, no analyst has increased his estimate for the current quarter, while two have revised their estimate downward. Our Zacks Consensus Estimate for the current quarter has remained flat at $1.01 per share in the same time period. Given the way analysts feel about Amphastar Pharmceuticals right now, this huge implied volatility could mean there\u2019s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-12-04T19:54:00+00:00", "sentiment": {"score": -0.24249446392059326, "confidence": 0.2967289984226227, "probabilities": {"positive": 0.05423453450202942, "negative": 0.2967289984226227, "neutral": 0.6490364670753479}}, "embedding": [-0.12590378522872925, -0.07385655492544174, 0.07330435514450073, -0.04834726080298424, -0.08787645399570465, -0.012868072837591171, 0.037228357046842575, 0.10517570376396179, 0.1083490401506424, 0.12839218974113464, -0.047778718173503876, 0.15961188077926636, -0.010145907290279865, 0.0799625813961029, -0.00566762313246727, 0.02721642330288887, 0.05327283591032028, -0.10339641571044922, -0.21092641353607178, 0.09252402186393738, 0.014566331170499325, 0.013006736524403095, -0.04276495799422264, -0.03773709759116173, 0.0679897740483284, 0.06865980476140976, -0.058756161481142044, 0.033994559198617935, -0.1824280321598053, -0.09080963581800461, -0.028142916038632393, 0.10473552346229553, 0.00024825590662658215, -0.09925064444541931, -0.115883469581604, 0.018475275486707687, -0.06712856888771057, 0.048278793692588806, 0.14772924780845642, 0.07265950739383698, -0.06659594178199768, 0.022511685267090797, -0.1619773656129837, -0.013126851990818977, -0.04422713443636894, -0.15704843401908875, 0.105990931391716, -0.10671919584274292, 0.0563887320458889, 0.01587243191897869, -0.10099279880523682, -0.06665146350860596, 0.08069655299186707, -0.0006373557262122631, -0.077158123254776, -0.10315236449241638, -0.1719459742307663, 0.021955348551273346, 0.08530358225107193, 0.07042054831981659, 0.018190275877714157, 0.04860268905758858, 0.03873635083436966, -0.0472954623401165, -0.042620472609996796, 0.021838592365384102, 0.1581157147884369, 0.028234567493200302, 0.015323420986533165, 0.0595054104924202, 0.1011313945055008, -0.0014397979248315096, -0.13857720792293549, -0.003524675965309143, -0.030635325238108635, 0.06323561072349548, 0.1234581395983696, -0.08830074965953827, 0.04353850334882736, -0.04344145208597183, 0.09297746419906616, -0.05264825373888016, -0.12293027341365814, 0.024686312302947044, 0.012758004479110241, -0.048486970365047455, 0.007904519326984882, -0.007991645485162735, 0.0934738963842392, -0.08876734972000122, 0.062030792236328125, -0.08516345918178558, -0.1162969321012497, -0.05475965887308121, 0.10954983532428741, 0.0455295667052269, -0.2048008143901825, 0.016163934022188187, -0.04682684317231178, 0.04794126749038696, 0.06428031623363495, 0.03653150796890259, -0.10039277374744415, -0.09462842345237732, 0.04392983391880989, -0.1997811496257782, 0.07669039070606232, -0.024771032854914665, -0.03623068705201149, 0.0729224681854248, -0.017719993367791176, 0.0771237388253212, -0.1217394471168518, 0.02141769975423813, -0.15352609753608704, 0.22320787608623505, 0.0563792884349823, -0.0072441715747118, 0.01584743522107601, -0.020139997825026512, -0.0637558326125145, 0.07971259206533432, -0.007708630990236998, -0.047846920788288116, -0.022513609379529953, 0.08487913012504578, -0.166203111410141, 1.352540697787417e-32, -0.0558009073138237, 0.06980722397565842, 0.06603077799081802, -0.05144054815173149, -0.03066059574484825, -0.004496356006711721, -0.026890162378549576, 0.008539191447198391, -0.03712569177150726, -0.05414707213640213, -0.1350223869085312, 0.1309882402420044, -0.015188204124569893, 0.06710965931415558, 0.04167121648788452, -0.08229488134384155, -0.037448979914188385, -0.03911444544792175, -0.018154587596654892, -0.11925459653139114, 0.06324277073144913, 0.05649489164352417, -0.14105752110481262, -0.05636407434940338, -0.09745195508003235, 0.015214421786367893, 0.031957343220710754, -0.07561708986759186, -0.10962705314159393, 0.03591274097561836, -0.13882532715797424, 0.09776075929403305, -0.07521666586399078, -0.08236008882522583, -0.022603217512369156, -0.027299700304865837, -0.05268780514597893, -0.007590670138597488, 0.12682539224624634, -0.003064413322135806, -0.07665180414915085, 0.06213553994894028, -0.2040923833847046, 0.02747301384806633, 0.1015612930059433, 0.03407248109579086, -0.08464450389146805, 0.12816104292869568, 0.020282959565520287, 0.12195788323879242, -0.023239944130182266, 0.0008270369144156575, 0.06458514928817749, 0.043940313160419464, -0.15375916659832, 0.059459246695041656, -0.033131565898656845, -0.12700743973255157, 0.05316680669784546, 0.11382892727851868, 0.11100005358457565, 0.07041133940219879, 0.03360361233353615, -0.020388029515743256, -0.10818801820278168, 0.05089420825242996, -0.04776787757873535, -0.07284510135650635, -0.028354233130812645, 0.060741156339645386, -0.026566483080387115, 0.022239675745368004, 0.1528613567352295, -0.1878167986869812, 0.047832004725933075, -0.08377033472061157, 0.04560953378677368, 0.10749205201864243, 0.140752375125885, -0.01532743126153946, 0.10811758041381836, -0.14694930613040924, 0.04406537860631943, -0.03495194762945175, -0.012403544038534164, -0.048062533140182495, -0.010956481099128723, -0.10542337596416473, -0.06613212823867798, 0.030146321281790733, 0.026910558342933655, 0.03596500679850578, -0.06180243939161301, 0.04360036924481392, 0.024496354162693024, -1.483719255183461e-32, 0.07783205807209015, -0.03595671430230141, 0.02695523016154766, 0.06635992974042892, 0.09035691618919373, 0.0790427029132843, 0.11838836222887039, 0.04793909937143326, -0.05981361120939255, -0.09258639812469482, -0.046808164566755295, 0.12695768475532532, 0.015448018908500671, 0.026070866733789444, 0.036277301609516144, -0.04367521405220032, 0.011699606664478779, -0.12198011577129364, 0.11331230401992798, -0.07720288634300232, -0.05540407449007034, 0.13328775763511658, -0.1743880808353424, 0.18769626319408417, 0.11238199472427368, 0.002199874259531498, -0.03283325582742691, 0.11591212451457977, 0.04462181031703949, 0.048737719655036926, -0.1289796531200409, 0.0458192303776741, -0.10929058492183685, 0.01918606646358967, 0.07007332146167755, 0.07567483931779861, 0.08214020729064941, 0.044961124658584595, -0.08345840871334076, 0.03348410874605179, -0.01568312756717205, -0.008300308138132095, 0.06321480870246887, 0.02719767391681671, 0.04498755931854248, 0.0804927796125412, 0.10468631982803345, 0.002620377577841282, 0.09784501791000366, -0.05267082154750824, 0.11152707040309906, 0.12566788494586945, -0.06409245729446411, 0.17089059948921204, -0.009954294189810753, -0.03867381811141968, -0.14464843273162842, -0.04186209663748741, -0.05809678137302399, 0.04034943878650665, 0.04510871320962906, 0.1032399833202362, 0.06256970763206482, -0.13458336889743805, -0.01105663925409317, -0.00922892615199089, -0.0021828478202223778, -0.16300462186336517, -0.012478683143854141, -0.09584994614124298, 0.017383582890033722, -0.17705078423023224, 0.0402943454682827, -0.17601199448108673, 0.016306322067975998, 0.08397382497787476, -0.03135496377944946, -0.16620449721813202, -0.03746211528778076, -0.04608532041311264, 0.03824811056256294, 0.05885276943445206, -0.04050959646701813, 0.0004030708223581314, -0.09213554859161377, 0.12442004680633545, -0.13659986853599548, 0.1294129341840744, -0.034070324152708054, 0.03929992392659187, -0.07131493091583252, -0.16623429954051971, -0.09943222254514694, 0.052485235035419464, -0.0001158243976533413, -1.0053565091538985e-07, 0.12265326082706451, -0.008933771401643753, 0.08121513575315475, 0.027668923139572144, 0.05533642694354057, 0.0108486982062459, 0.046067014336586, 0.06444954872131348, 0.18867333233356476, 0.1579252928495407, 0.2056310474872589, 0.0681634321808815, -0.15161021053791046, -0.016682889312505722, -0.04124269261956215, 0.033355146646499634, -0.09271693229675293, 0.05800720676779747, -0.020931396633386612, 0.06639207154512405, -0.02502628229558468, 0.019840946421027184, 0.022007178515195847, -0.09807072579860687, 0.1204318180680275, 0.045308828353881836, -0.06660977751016617, 0.042902421206235886, -0.04192652180790901, 0.14052100479602814, 0.03768039867281914, -0.04784709960222244, 0.016261596232652664, 0.08944642543792725, -0.08164596557617188, -0.016239453107118607, 0.020280439406633377, 0.06050831079483032, -0.029543951153755188, -0.06651042401790619, -0.10259754955768585, -0.13308332860469818, -0.05512663722038269, -0.001231849193572998, -0.026627905666828156, -0.14022672176361084, -0.0467589870095253, 0.012528018094599247, 0.04840809106826782, -0.028692489489912987, -0.01688448153436184, -0.03226197883486748, 0.0427108034491539, 0.08404660224914551, -0.014295616187155247, 0.04735131561756134, -0.1306522935628891, -0.12588295340538025, -0.06266448646783829, 0.04465211182832718, 0.1398385614156723, -0.19250383973121643, -0.04736293852329254, 0.17911306023597717], "changes": {"1wk": -1.6478545255269987, "1mo": -18.05869105592975}}, {"text": "Why Amphastar Pharmaceuticals (AMPH) Is One of the Most Profitable Pharmaceutical Stocks Right Now? Laiba Immad Sun, Dec 1, 2024, 12:27 AM 5 min read In This Article: AMPH -4.24% We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now . In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against the other most profitable pharmaceutical stocks. The Pharmaceutical Industry: Growth, Innovation, and Emerging Challenges Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the term \"defensive\" a step further than practically any other industry. Improvements in medical technology, medications, and therapeutic approaches have changed the course of patient care. As the need for quick results has grown, pharmaceutical corporations in particular have drawn much attention. Global pharmaceutical manufacturing was estimated to be worth $516.48 billion in 2022, according to a Grand View Research analysis. From 2023 to 2030, the industry is expected to expand at a compound annual growth rate (CAGR) of 7.63%. The biopharma industry now has the most extensive and varied clinical pipeline, due to decades of groundbreaking research. In 2012, there were 3,200 distinct medications under development; by 2022, that number had nearly doubled to 6,100. The average cost of producing a single treatment is over $1 billion, while just 14% of medications in clinical trials reach FDA clearance, according to MIT research. This could be a game-changer for AI. To identify the optimum medicine combinations, generative AI, for instance, helps researchers identify illness patterns in large data sets and explore a far greater number of possible compounds than traditional approaches can. Additionally, according to PwC, AI-driven analytics and automation could cut operational costs by more than 30% and process timeframes by 60\u201370%. In a similar vein, the market has grown significantly due to consumer interest in weight-loss medications like Ozempic and Wegovy. According to a recent study in the scientific journal Addiction, GLP-1 medications may reduce the prevalence of alcohol and opioid addiction by as much as 50%. Additionally, these medications are being evaluated for Alzheimer's disease and other disorders that are frequently associated with obesity. The development of GLP-1 is becoming crucial for pharmaceutical businesses that want to be leaders in fields like cardiovascular and renal health. Competition with the leading companies in the anti-obesity business, which is expected to grow to $130 billion by 2030, is no longer the main emphasis. The possibility of additional participants entering the field is growing along with the possible applications of GLP-1s. Story Continues The pharmaceutical industry faces challenges despite appearing robust. Biotech and pharma funding dropped 48.6% in 2022 compared to 2021, with IPO proceeds also declining amid market volatility. While 2020 and 2021 saw drug-developer IPOs raise $46.5 billion, surpassing the previous eight years combined, investor caution has increased. In 2024, drug developers raised $2 billion through IPOs by September 3, a 24% year-over-year increase. However, two-thirds of these funds came early in the year, with proceeds falling sharply later, reducing their share of U.S. IPO proceeds from 17% in February to 6.5%. In his October 7 remarks, Tim Hunt, CEO of the Alliance for Regenerative Medicine, highlighted increased 2024 investment in cell and gene therapies, noting that 13 of the 15 largest pharma companies are active in this space. With numerous patents expiring, these therapies offer potential revenue opportunities. However, Q2 2024 saw a 38% drop in cell and gene therapy deals compared to 2023, alongside fewer patent applications. Despite these challenges, the field remains a strong investment prospect. A close-up of a woman's hand syringe containing a bio-pharmaceutical drug. Our Methodology Our methodology focuses on identifying high-growth stocks by applying a rigorous Stock Analysis filter. We considered companies with positive net income growth for 5 years and then ranked them accordingly. We also measured hedge fund sentiment around each stock according to Insider Monkey\u2019s database of 900 as of Q3 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) Net Income Growth 5Y: 24.93% Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that specializes in the development, manufacturing, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company operates primarily in the United States, China, and France. AMPH is one of the most profitable stocks on our list. In Q3 2024, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) reported net revenues of $191.2 million, a 6% year-over-year increase, driven by strong sales of products like Primatene Mist ($26.1 million), BAQSIMI ($40.4 million), and the launch of Albuterol MDI. Primatene Mist is on track for $100 million in annual sales by the end of 2024, and the corporation plans to expand the BAQSIMI market and strengthen its sales force. Despite a decrease in adjusted net income to $49.6 million ($0.96 per share) due to lower gross margins (53% vs. 60% in 2023) and higher operating expenses, the company generated $60 million in cash flow and repurchased $35 million worth of shares. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) also announced a $50 million share buyback program. Ongoing discussions with the FDA regarding its insulin pipeline are expected to drive future growth. Street analysts hold a consensus Strong Buy rating on the stock, with an average price target of $63.67 (high: $70, low: $55), implying a 40.89% upside from the current price of $45.19. Overall, AMPH ranks 5th on our list of most profitable pharmaceutical stocks right now. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMPH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-30T21:27:55+00:00", "sentiment": {"score": 0.6330320313572884, "confidence": 0.6844500303268433, "probabilities": {"positive": 0.6844500303268433, "negative": 0.0514179989695549, "neutral": 0.26413199305534363}}, "embedding": [0.004739817697554827, -0.10870468616485596, -0.05567566305398941, -0.03262578696012497, -0.10229350626468658, -0.012505996972322464, -0.06419620662927628, 0.23446068167686462, 0.1526435911655426, 0.14048756659030914, -0.20399388670921326, 0.07458565384149551, 0.04394805058836937, 0.04316171258687973, -0.11993259191513062, 0.07699351757764816, 0.0696389302611351, -0.04040169715881348, -0.10484695434570312, -0.007824528962373734, 0.0219358392059803, 0.05411040782928467, 0.14977353811264038, -0.04385273903608322, -0.03281756490468979, 0.09290121495723724, -0.1105860248208046, -0.11953495442867279, -0.14900244772434235, -0.0877508744597435, 0.09658493101596832, 0.15046630799770355, 0.09123195707798004, -0.08114931732416153, -0.06516814231872559, 0.034908801317214966, -0.16365130245685577, 0.13413049280643463, 0.06874160468578339, 0.004722842015326023, -0.0018369329627603292, -0.03827044740319252, -0.11142021417617798, -0.00961713120341301, 0.08345670998096466, -0.2256629765033722, -0.1054220125079155, 0.014981985092163086, 0.11025844514369965, 0.15397481620311737, -0.19266292452812195, -0.1186286211013794, 0.014783557504415512, 0.09933055192232132, -0.014536083675920963, -0.08507470786571503, -0.07027576863765717, -0.04982811585068703, -0.027356863021850586, 0.1019354909658432, -0.007086978293955326, -0.037995897233486176, 0.03545231372117996, -0.10280965268611908, 0.10529805719852448, 0.05053636059165001, 0.07925177365541458, -0.07541322708129883, -0.07937541604042053, -0.018012724816799164, 0.08693525195121765, -0.013839565217494965, -0.029079483821988106, 0.08717116713523865, -0.01831797882914543, 0.0706942230463028, 0.085250124335289, 0.08933047205209732, 0.15955346822738647, -0.09548263996839523, 0.1687283217906952, 0.0007415320724248886, -0.04488101601600647, 0.0668424442410469, 0.0001323837786912918, -0.0089286919683218, 0.04900271072983742, 0.16745540499687195, 0.11737596988677979, -0.02475607767701149, 0.0328567773103714, 0.01649037003517151, -0.0004173051565885544, -0.07757240533828735, 0.002859611064195633, 0.003788979724049568, -0.09400355815887451, 0.013821324333548546, 0.0744381919503212, 0.004546857438981533, 0.05753495916724205, 0.024792775511741638, 0.021243786439299583, -0.13903822004795074, -0.029752127826213837, -0.09234945476055145, 0.10795846581459045, -0.06978300213813782, 0.06279535591602325, 0.07507788389921188, -0.11421045660972595, 0.041980694979429245, -0.04571514576673508, 0.04343933239579201, -0.05099701136350632, 0.11811859905719757, 0.04516033083200455, 0.10829061269760132, 0.041198115795850754, 0.14973917603492737, -0.011335772462189198, -0.01878064125776291, 0.03896977752447128, -0.0959457978606224, -0.01592107117176056, 0.046603839844465256, -0.2372298538684845, 5.1863490340950894e-33, -0.0068823061883449554, 0.030072230845689774, 0.05861197039484978, -0.01983114704489708, -0.0003813542425632477, -0.0156878549605608, 0.008394647389650345, 0.06006030738353729, -0.0668189525604248, -0.13390518724918365, -0.19700995087623596, 0.10258129239082336, -0.10096543282270432, 0.18777349591255188, 0.11234050989151001, -0.10310229659080505, 0.03610170632600784, 0.0532325878739357, -6.754789501428604e-05, -0.1533346027135849, -0.11893977969884872, -0.10851803421974182, -0.012763858772814274, 0.11049646884202957, -0.09472524374723434, 0.023591943085193634, -0.06189190596342087, 0.025601744651794434, 0.018989361822605133, -0.014056514017283916, -0.05151418596506119, 0.06224719062447548, -0.026156052947044373, -0.09551722556352615, -0.08304525911808014, -0.10693703591823578, -0.09588250517845154, -0.07956958562135696, 0.07141001522541046, 0.05025136098265648, -0.15092945098876953, 0.06824462115764618, -0.04288604483008385, 0.021379239857196808, -0.004312969744205475, 0.0720691904425621, -0.061406493186950684, -0.02596803940832615, -0.04564100131392479, 0.029697934165596962, -0.09001821279525757, 0.014433511532843113, 0.05401373282074928, -0.04217170178890228, -0.01663188636302948, 0.08170713484287262, -0.21272841095924377, -0.15181194245815277, 0.09659423679113388, 0.1426561027765274, -0.03931573033332825, 0.1532595008611679, -0.026121266186237335, 0.09254752099514008, -0.07720470428466797, 0.14621931314468384, 0.05440264195203781, -0.04239153489470482, -0.05962264910340309, 0.20749463140964508, 0.09324079006910324, -0.06489624083042145, 0.03227338567376137, -0.06345559656620026, 0.11893968284130096, 0.0005995780229568481, 0.08201945573091507, -0.04469519853591919, -0.013918599113821983, 0.043788447976112366, -0.058657966554164886, 0.04695863276720047, -0.1240285187959671, 0.08013790845870972, -0.039476972073316574, 0.0020716211292892694, 0.04813690483570099, 0.026878181844949722, -0.10614608228206635, -0.111781045794487, -0.1292998194694519, -0.015225215815007687, -0.037866249680519104, 0.04942343011498451, -0.0038049686700105667, -6.385601227773449e-33, -0.013999048620462418, -0.041500337421894073, 0.03833618387579918, -0.012326219119131565, 0.09984546154737473, -0.00538242980837822, 0.017724644392728806, -0.22533532977104187, 0.13417348265647888, 0.006352294236421585, -0.016724567860364914, 0.039431970566511154, 0.05811719968914986, 0.03876383975148201, -0.0843835324048996, 0.013787798583507538, -0.03407015651464462, -0.08406206220388412, 0.0010806731879711151, -0.0372425839304924, 0.05612830072641373, 0.20790308713912964, -0.1313098669052124, 0.07846422493457794, -0.004350563976913691, 0.031872235238552094, -0.03097338229417801, 0.05980093404650688, 0.05928933247923851, 0.02185310237109661, -0.07779891788959503, 0.07803095132112503, -0.18184800446033478, 0.047230228781700134, -0.030142800882458687, 0.07989664375782013, 0.038077499717473984, -0.103139229118824, 0.013521287590265274, -0.061143383383750916, 0.08348359167575836, 0.04265652596950531, -0.09834346175193787, -0.03298216685652733, 0.09325743466615677, -0.11004896461963654, 0.05157039687037468, 0.03341531753540039, 0.15463268756866455, -0.05131503567099571, 0.03556950390338898, 0.09889157116413116, -0.0219934843480587, -0.03431183472275734, -0.08739098161458969, -0.00040380656719207764, -0.04550924152135849, -0.0744452103972435, -0.09754713624715805, -0.009518589824438095, -0.0738380178809166, 0.0539800226688385, 0.044492051005363464, 0.017926590517163277, -0.07302142679691315, 0.055055420845746994, 0.2216428518295288, -0.014299854636192322, 0.03149453178048134, -0.14096403121948242, 0.014881419949233532, -0.07181502133607864, 0.15799489617347717, -0.0019492413848638535, -0.09160478413105011, 0.10809106379747391, -0.07128366082906723, -0.13880756497383118, -0.09564752876758575, -0.050893694162368774, 0.11016348004341125, -0.07361315190792084, -0.0050562908872962, -0.04377742484211922, -0.13610386848449707, 0.08458450436592102, 0.0663340613245964, -0.0294792503118515, -0.07701403647661209, 0.047763727605342865, -0.11158345639705658, -0.09554943442344666, -0.13375407457351685, 0.07095114141702652, -0.029406150802969933, -1.005799532549645e-07, 0.21870285272598267, -0.07732446491718292, 0.15405482053756714, -0.004086418077349663, 0.1333974003791809, -0.04879412427544594, -0.06943795084953308, 0.1447634994983673, -0.007993211038410664, 0.1528589427471161, 0.05685873702168465, 0.08345727622509003, -0.10879450291395187, 0.11409171670675278, -0.036008886992931366, 0.07384949177503586, -0.057204313576221466, 0.11331787705421448, -0.07092293351888657, -0.0045205652713775635, -0.045800354331731796, 0.06869323551654816, 0.004621993750333786, -0.08051571249961853, 0.056365832686424255, -0.13945135474205017, -0.01914568617939949, -0.09142034500837326, -0.10939154028892517, 0.08256830275058746, 0.10789680480957031, 0.009610429406166077, 0.10679228603839874, 0.03797825425863266, 0.07782257348299026, -0.19683493673801422, 0.07041937857866287, -0.023148320615291595, -0.09873197972774506, 0.008432907983660698, -0.026991920545697212, 0.102892205119133, -0.03381984308362007, 0.02788642793893814, 0.018228909000754356, -0.12611445784568787, -0.08371990919113159, -0.010400605387985706, 0.09267570078372955, -0.07103332877159119, 0.13070333003997803, 0.06876908242702484, 0.03730852156877518, -0.09628799557685852, 0.05013414844870567, 0.11243745684623718, -0.09798748791217804, -0.141754150390625, -0.08125456422567368, -0.06598949432373047, 0.12057715654373169, -0.2472798377275467, 0.20597518980503082, 0.02101869136095047], "changes": {"1wk": -4.533569709308933, "1mo": -19.703576079055026}}, {"text": "Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings Zacks Equity Research Thu, Nov 7, 2024, 2:00 AM 3 min read In This Article: AMPH -4.24% For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-ago quarter. The reported revenue represents a surprise of -2.51% over the Zacks Consensus Estimate of $196.15 million. With the consensus EPS estimate being $1.01, the EPS surprise was -4.95%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Amphastar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net revenues- Primatene MIST : $26.06 million versus $23.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change. Net revenues- Epinephrine : $21.34 million compared to the $27.30 million average estimate based on two analysts. The reported number represents a change of +5.7% year over year. Net revenues- Lidocaine : $15.88 million compared to the $13.62 million average estimate based on two analysts. The reported number represents a change of +2.3% year over year. Net revenues- Phytonadione : $11.72 million versus the two-analyst average estimate of $9.43 million. The reported number represents a year-over-year change of +57.4%. Net revenues- API (Active pharmaceutical ingredients) : $1.46 million compared to the $2.89 million average estimate based on two analysts. The reported number represents a change of -65.1% year over year. Net revenues- Enoxaparin : $5.62 million versus the two-analyst average estimate of $6.08 million. The reported number represents a year-over-year change of -27.1%. Net revenues- Naloxone : $4.04 million compared to the $3.83 million average estimate based on two analysts. The reported number represents a change of -14.4% year over year. Net revenues- Total finished pharmaceutical products net revenues : $187.36 million versus the two-analyst average estimate of $192.57 million. The reported number represents a year-over-year change of +26.9%. Net revenues- Glucagon : $26.79 million versus the two-analyst average estimate of $26.65 million. The reported number represents a year-over-year change of -9.2%. Story Continues View all Key Company Metrics for Amphastar here>>> Shares of Amphastar have returned +11.4% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-06T23:00:12+00:00", "sentiment": {"score": 0.23664623498916626, "confidence": 0.48853424191474915, "probabilities": {"positive": 0.48853424191474915, "negative": 0.2518880069255829, "neutral": 0.2595777213573456}}, "embedding": [0.024974476546049118, -0.053069692105054855, -0.013405483216047287, 0.00775556918233633, -0.09354443848133087, 0.031779199838638306, 0.04692281782627106, 0.14528140425682068, 0.12837538123130798, 0.12740680575370789, -0.1307632476091385, 0.048016589134931564, 0.059616465121507645, -0.029581909999251366, -0.06923644244670868, 0.019717436283826828, 0.11027956008911133, -0.05292122811079025, -0.10950443148612976, -0.007406136021018028, 0.08327699452638626, -0.018381016328930855, 0.10011203587055206, -0.07759416103363037, 0.10532067716121674, 0.0700397938489914, -0.20416046679019928, 0.059969693422317505, -0.1697709858417511, -0.12120562046766281, -0.036528266966342926, 0.06891646236181259, 0.06727036833763123, -0.07146626710891724, -0.08880551159381866, -0.010244677774608135, -0.03343050554394722, 0.16019472479820251, 0.09493619203567505, 0.0675726979970932, -0.02527105249464512, 0.006873637437820435, -0.13799923658370972, -0.09949387609958649, -0.023728955537080765, -0.16193082928657532, -0.017333481460809708, 0.002358092227950692, -0.019506119191646576, 0.09683383256196976, -0.10659117996692657, -0.08075189590454102, 0.08419880270957947, 0.02633868157863617, -0.05011172592639923, -0.00019355956465005875, -0.12485314160585403, 0.021713903173804283, 0.0388086698949337, 0.026043370366096497, -0.08779136836528778, 0.03264987841248512, -0.0005564659368246794, -0.011159236542880535, 0.16647091507911682, -0.0013853153213858604, 0.005712808109819889, -0.02934548631310463, -0.0952400267124176, 0.006404270883649588, 0.08724939823150635, -0.050665732473134995, -0.08340616524219513, -0.0533587783575058, -0.11568368226289749, 0.05084477365016937, 0.15174250304698944, 0.06221144646406174, 0.10234303027391434, -0.094390869140625, 0.07839605212211609, 0.010653505101799965, -0.15506847202777863, -0.04462447389960289, 0.013435536995530128, -0.02418629080057144, 0.15136098861694336, 0.08162199705839157, -0.00883711501955986, -0.01060622651129961, 0.0740095004439354, -0.01637890562415123, 0.027383431792259216, -0.051189105957746506, 0.10270588845014572, 0.02035769820213318, -0.12665113806724548, -0.02621334232389927, 0.08203597366809845, 0.06914636492729187, 0.1038622260093689, 0.09169204533100128, -0.10698668658733368, -0.1848958134651184, 0.015749476850032806, -0.11450207978487015, 0.14262744784355164, 0.058745529502630234, -0.016632739454507828, 0.06658463180065155, -0.03497643768787384, 0.06397242844104767, -0.10181856155395508, -0.008357816375792027, -0.018474461510777473, 0.11639972031116486, -0.04478822648525238, 0.03889138251543045, 0.10240258276462555, -0.023000545799732208, 0.026751989498734474, 0.02796005830168724, 0.0947495698928833, 0.01936843991279602, -0.027593594044446945, 0.05911022052168846, -0.16527977585792542, 1.1185745633667707e-32, -0.021571435034275055, 0.03374497592449188, 0.025370242074131966, -0.12461834400892258, 0.009272643364965916, 0.05644159018993378, -0.018510181456804276, 0.08908195048570633, -0.01758584938943386, -0.027252791449427605, -0.1391037106513977, 0.17758320271968842, -0.009674539789557457, -0.009339937940239906, 0.009970378130674362, -0.038211435079574585, -0.059456177055835724, 0.06898923218250275, -0.025529000908136368, -0.13681387901306152, -0.018119871616363525, -0.07871286571025848, -0.028394408524036407, 0.08723671734333038, -0.05211414396762848, -0.05696588009595871, -0.04245903342962265, 0.10367988795042038, -0.06941963732242584, 0.022205254063010216, 0.046987250447273254, 0.018738791346549988, 0.056640349328517914, -0.10397818684577942, -0.14246757328510284, -0.14223089814186096, -0.0017368616536259651, -0.04915764927864075, 0.14380264282226562, 0.01985313557088375, -0.1284237504005432, 0.08111904561519623, -0.07142060995101929, -0.11187435686588287, -0.08854220807552338, 0.053657449781894684, -0.07918047159910202, 0.035885900259017944, 0.0644831582903862, 0.022120174020528793, -0.04563842713832855, 0.01602199114859104, 0.010720265097916126, 0.01653432846069336, -0.0706704705953598, 0.10115808248519897, -0.054271116852760315, -0.15661053359508514, 0.08547119051218033, 0.1653362661600113, -0.06624820828437805, 0.17918923497200012, 0.036897070705890656, -0.10090236365795135, -0.1598571240901947, 0.15292988717556, 0.06702698022127151, 0.10255299508571625, -0.018560495227575302, 0.11279311776161194, 0.0024219853803515434, -0.1022743284702301, 0.07283880561590195, -0.05026299133896828, 0.12395761907100677, -0.0459323413670063, -0.002233758568763733, 0.04241020604968071, 0.03609837219119072, 0.09758619964122772, 0.06496502459049225, 0.02405911311507225, -0.0011927327141165733, -0.020028959959745407, -0.04576462507247925, 0.03814609348773956, 0.09601478278636932, -0.030707238242030144, 0.024340283125638962, 0.007038143463432789, 0.03538713604211807, -0.009039218537509441, -0.16849768161773682, 0.03215206414461136, -0.06088954210281372, -1.0827197816147831e-32, -0.03113408200442791, 0.0972554087638855, -0.008956028148531914, 0.032509587705135345, -0.009397085756063461, 0.0077084931544959545, 0.10200096666812897, -0.02164503186941147, -0.041643619537353516, -0.03346173092722893, 0.02133745141327381, 0.03464473783969879, -0.12137895822525024, 0.018456507474184036, 0.01630934700369835, 0.0010572830215096474, 0.04173300415277481, -0.1466754674911499, 0.04565364867448807, -0.01070109847933054, 0.02275354228913784, 0.16040480136871338, -0.11152629554271698, 0.11016637086868286, -0.019435184076428413, -0.00023258925648406148, -0.014145520515739918, 0.08478148281574249, 0.02993694692850113, -0.04969021677970886, -7.228739559650421e-05, 0.006099397782236338, -0.15730033814907074, 0.008442448452115059, -0.023662064224481583, -0.008543523028492928, 0.00048741046339273453, -0.14162802696228027, -0.04273437708616257, -0.031591929495334625, 0.03153152018785477, 0.006792628206312656, 0.025605032220482826, -0.04170272499322891, 0.10465028882026672, 0.0017479564994573593, 0.02318383753299713, -0.0520247183740139, 0.04143896698951721, 0.00939149223268032, 0.010146385058760643, 0.053242988884449005, -0.08657503128051758, 0.059419095516204834, -0.11596903204917908, 0.004856330808252096, -0.019380196928977966, 0.04117933660745621, -0.07353530824184418, 0.02703315205872059, 0.05087697505950928, 0.074155293405056, 0.022785786539316177, -0.01838015951216221, -0.044665541499853134, 0.0054668840020895, 0.069607675075531, -0.1197502389550209, 0.0454053059220314, -0.11216793954372406, -0.04516259580850601, -0.11735616624355316, 0.09735466539859772, -0.09978600591421127, -0.12149874866008759, 0.1633281260728836, -0.027209676802158356, -0.08297548443078995, -0.054353535175323486, -0.02796829678118229, 0.033491771668195724, 0.12553249299526215, 0.018200479447841644, -0.08924026787281036, -0.07080397009849548, 0.09988708794116974, 0.0038097957149147987, -0.017819389700889587, -0.11648370325565338, 0.09114022552967072, -0.11032401025295258, -0.200088769197464, -0.16022835671901703, 0.08576048910617828, 0.11422822624444962, -1.0070607459056191e-07, 0.0666007474064827, 0.017352508381009102, 0.13318656384944916, 0.07863515615463257, 0.07756148278713226, -0.05060045048594475, 0.052550047636032104, 0.09479580819606781, 0.06373922526836395, 0.06450998783111572, 0.1183818131685257, 0.011773069389164448, -0.19013990461826324, 0.09453894942998886, -0.08060423284769058, 0.07629448175430298, -0.06840789318084717, 0.07963068783283234, 0.006693696137517691, -0.05561340972781181, -0.030161619186401367, 0.11995035409927368, -0.01971946656703949, -0.10230721533298492, 0.10991190373897552, -0.05484640225768089, -0.06599578261375427, 0.027098391205072403, -0.07512390613555908, 0.01598009653389454, 0.10499706119298935, -0.012462453916668892, 0.08894230425357819, -0.06655001640319824, 0.06344744563102722, -0.07065249979496002, 0.0029651690274477005, 0.06085512787103653, 0.011314375326037407, 0.08400584757328033, -0.03381256014108658, -0.008399393409490585, 0.003080829046666622, 0.040762513875961304, 0.011668656021356583, -0.08647605776786804, -0.1762951910495758, 0.05396788567304611, 0.05150127783417702, -0.14906124770641327, 0.21842879056930542, -0.05190134793519974, 0.034282930195331573, -0.07273329794406891, 0.045762211084365845, -0.027875401079654694, -0.18094730377197266, -0.0892636775970459, -0.10640023648738861, 0.025235643610358238, 0.11801766604185104, -0.2027154266834259, 0.023365287110209465, 0.02322516404092312], "changes": {"1wk": -14.831463965041944, "1mo": -17.977531862365158}}, {"text": "Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference ACCESS Newswire \u00b7 Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Wed, Nov 27, 2024, 12:05 AM 3 min read In This Article: AMPH -4.24% Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4 th , 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 30 days following the presentation. About Amphastar: Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com . The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene MIST \u00ae , Amphadase \u00ae , Cortrosyn \u00ae , REXTOVY \u00ae and BAQSIMI \u00ae are the property of Amphastar Pharmaceuticals, Inc. Forward Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI \u00ae , including its potential for continued revenue growth, the success of our integration of BAQSIMI \u00ae , the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as \"may,\" \"might,\" \"will,\" \"could,\" \"would,\" \"should,\" \"anticipate,\" \"predict,\" \"potential,\" \"continue,\" \"expect,\" \"intend,\" \"plan,\" \"project,\" \"believe,\" \"estimate,\" and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST \u00ae or that we will continue to experience significant sales of BAQSIMI \u00ae . You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Story Continues Contact: Bill Peters Chief Financial Officer (909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-26T21:05:00+00:00", "sentiment": {"score": 0.030179052613675594, "confidence": 0.043293967843055725, "probabilities": {"positive": 0.043293967843055725, "negative": 0.01311491522938013, "neutral": 0.9435911178588867}}, "embedding": [-0.0860149934887886, -0.09514836221933365, -0.07497651875019073, -0.10066735744476318, -0.09273865073919296, -0.003913860768079758, 0.014204224571585655, 0.128916934132576, 0.06195037066936493, 0.021481633186340332, -0.05179605633020401, 0.09348249435424805, 0.10144263505935669, 0.07214152812957764, -0.08620171248912811, 0.012149224057793617, 0.046275846660137177, 0.03900603950023651, -0.1321495622396469, 0.022917963564395905, 0.05621536448597908, 0.14279070496559143, 0.06537380814552307, 0.011333951726555824, -0.05539144575595856, 0.06491178274154663, -0.12922117114067078, -0.001550596673041582, -0.09846284240484238, -0.06389177590608597, 0.01340221706777811, 0.12787708640098572, 0.037086665630340576, -0.14110910892486572, 0.11030478030443192, 0.11869622766971588, -0.09508012235164642, 0.07214897125959396, 0.007428226061165333, 0.047446466982364655, 0.06576652079820633, -0.08731265366077423, -0.12669885158538818, -0.04148697108030319, 0.03179897740483284, -0.12381701916456223, -0.03737135976552963, -0.004899292252957821, 0.007979759946465492, 0.20739209651947021, -0.14814645051956177, -0.13027241826057434, 0.06678267568349838, 0.12911918759346008, -0.06398898363113403, -0.08250190317630768, -0.14627856016159058, -0.049820102751255035, -0.03827682137489319, 0.011384566314518452, -0.04187498986721039, -0.028486577793955803, 0.02072763256728649, 0.012144338339567184, 0.06905379146337509, 0.05439486354589462, 0.11567170917987823, -0.13295204937458038, -0.0427367202937603, -0.042135268449783325, 0.05281226336956024, -0.1256115585565567, -0.004274739418178797, 0.2737325429916382, -0.11432498693466187, 0.16598162055015564, 0.2584502100944519, 0.039076387882232666, 0.087396040558815, -0.08491750061511993, 0.05120913311839104, 0.11923334002494812, -0.021759919822216034, -0.047003842890262604, -0.0681283101439476, 0.0370091013610363, -0.003577397670596838, 0.08829131722450256, 0.01845875382423401, -0.05405681952834129, -0.02647746168076992, -0.029195167124271393, -0.011697283945977688, -0.10650041699409485, 0.04056267440319061, -0.14028432965278625, -0.10495896637439728, 0.07113981246948242, 0.08264072239398956, -0.011073309928178787, -0.03538371995091438, -0.00806787982583046, -0.12455114722251892, -0.11499124765396118, -0.03196967765688896, -0.12430604547262192, 0.021281011402606964, 0.07475559413433075, 0.0475175678730011, 0.0523398220539093, -0.0673346146941185, 0.13420027494430542, 0.0355614498257637, -0.053455885499715805, -0.06049581244587898, 0.21810360252857208, -0.051359884440898895, 0.016486946493387222, 0.18898159265518188, -0.0867917388677597, -0.008752105757594109, -0.03921502083539963, 0.010721077211201191, -0.12732255458831787, 0.01943458430469036, 0.031039603054523468, -0.19566431641578674, 7.654927945782187e-33, 0.002766198478639126, 0.07730637490749359, 0.06314997375011444, -0.003427548334002495, 0.03059035912156105, 0.0355851836502552, 0.017369873821735382, 0.04916566237807274, -0.08729356527328491, -0.059724293649196625, -0.10081522166728973, 0.17929226160049438, 0.02344249188899994, 0.06328750401735306, -0.13504847884178162, -0.07417004555463791, -0.0443844348192215, 0.020784815773367882, 0.0288265198469162, -0.17145973443984985, -0.08492955565452576, 0.07446826994419098, -0.07744316756725311, 0.17601662874221802, -0.06974577158689499, -0.01181638240814209, -0.016859225928783417, 0.049326058477163315, -0.028096366673707962, 0.06157922372221947, 0.030098965391516685, 0.0659676343202591, 0.013765663839876652, -0.17688268423080444, -0.09512051939964294, -0.11460833996534348, -0.11567586660385132, -0.14011839032173157, 0.06800569593906403, 0.039027139544487, -0.03519057482481003, 0.031799621880054474, -0.1532115638256073, 0.06648968160152435, 0.0068256244994699955, -0.0892258882522583, -0.08448831737041473, 0.046821121126413345, 0.12467656284570694, -0.047821179032325745, -0.07649923861026764, 0.017935732379555702, 0.06295383721590042, -0.09455530345439911, -0.030082620680332184, 0.02018139697611332, -0.1807761937379837, -0.13558079302310944, 0.05383271351456642, 0.15858247876167297, -0.08336541801691055, 0.07772737741470337, -0.07741642743349075, 0.009799744002521038, -0.10571794956922531, -0.02280672825872898, 0.034508317708969116, -0.033054109662771225, 0.012152405455708504, 0.019601628184318542, 0.07906882464885712, -0.03855111822485924, 0.08439603447914124, -0.007550974376499653, 0.0941387414932251, -0.1125103086233139, 0.05658136308193207, 0.1360844373703003, -0.0004789326339960098, 0.015468426048755646, -0.046111591160297394, 0.0748988538980484, -0.0353274829685688, 0.10197989642620087, -0.08953563868999481, 0.020169289782643318, 0.10125918686389923, -0.00990931037813425, -0.13752949237823486, -0.0854158103466034, -0.03682899847626686, 0.008860589005053043, -0.17379063367843628, 0.13981972634792328, -0.010890204459428787, -9.325168032398406e-33, 0.07479573786258698, -0.005996287800371647, -0.06975924968719482, -0.005884281359612942, 0.029646284878253937, 0.012834268622100353, 0.21461887657642365, -0.023321205750107765, 0.04872380569577217, -0.13912838697433472, 0.07916123420000076, 0.055602412670850754, -0.06933452188968658, -0.07111793756484985, -0.0924094021320343, 0.05548354983329773, 0.026760801672935486, -0.044032685458660126, -0.014424718916416168, 0.0984649509191513, 0.05601271241903305, 0.17824670672416687, -0.07393445819616318, 0.041696153581142426, 0.04172033816576004, -0.005627054255455732, 0.022678757086396217, 0.047899626195430756, 0.03808245062828064, 0.07382349669933319, -0.0837898701429367, 0.0366053581237793, -0.24396899342536926, 0.011323146522045135, 0.0037908218801021576, -0.046332940459251404, 0.05101291090250015, -0.18306106328964233, -0.06944315880537033, -0.11874321848154068, 0.040667541325092316, 0.04337816685438156, 0.017476242035627365, 0.056880101561546326, 0.12228652834892273, -0.00735216261819005, 0.102382130920887, -0.08545822650194168, 0.04747508093714714, 0.04670321196317673, -0.024259725585579872, 0.010601365938782692, -0.007470616139471531, 0.040880151093006134, -0.11393161118030548, 0.02882484346628189, -0.008373323827981949, -0.006538092158734798, -0.09173101931810379, 0.032429181039333344, 0.08887581527233124, 0.05697345733642578, 0.038537751883268356, -0.09638167917728424, 0.02508903667330742, 0.05313652753829956, 0.1104373037815094, -0.07909877598285675, 0.17748723924160004, -0.10916633158922195, -0.028878096491098404, -0.10995899140834808, 0.05059089884161949, -0.09722326695919037, -0.12846705317497253, 0.03397737443447113, -0.014744102954864502, -0.09930487722158432, -0.14196908473968506, -0.029731690883636475, 0.05774785578250885, 0.10033402591943741, -0.045480918139219284, 0.10736323893070221, 0.02705450728535652, 0.08195716887712479, -0.0012457435950636864, 0.026636481285095215, -0.051470935344696045, 0.08078166842460632, -0.10375654697418213, -0.1162026971578598, -0.13908876478672028, 0.14817845821380615, 0.01710834726691246, -1.0072182021758636e-07, 0.13744182884693146, 0.010980330407619476, -0.000661325640976429, 0.04220752790570259, 0.1044267788529396, -0.010435696691274643, -0.05230587720870972, -0.0007070116698741913, 0.02031765691936016, 0.14447514712810516, 0.07988446205854416, 0.161178857088089, -0.0790519192814827, 0.024947810918092728, -0.027017200365662575, 0.020078789442777634, -0.10566163063049316, 0.08256395161151886, -0.06645631790161133, -0.019386230036616325, -0.17348967492580414, 0.08251261711120605, 0.004775512032210827, -0.03303530067205429, -0.016644127666950226, -0.023053273558616638, 0.04549776017665863, -0.10062505304813385, -0.0044434089213609695, -0.023116901516914368, -0.044834211468696594, 0.050825633108615875, 0.09511755406856537, -0.0424017570912838, -0.0023836493492126465, -0.11126643419265747, 0.07337497174739838, 0.10583162307739258, 0.04951558634638786, 0.08147986233234406, -0.03931336849927902, -0.04556792974472046, 0.01874515786767006, 0.10949495434761047, -0.007161328569054604, -0.03784821182489395, -0.17888620495796204, 0.06336341798305511, -0.033516038209199905, 0.012093323282897472, 0.11196161806583405, -0.07303465902805328, 0.021466867998242378, -0.11639458686113358, -0.03164784982800484, 0.0424787774682045, -0.11040560901165009, -0.146034836769104, 0.07653627544641495, 0.02773432806134224, 0.13238835334777832, -0.07105699181556702, 0.21322351694107056, -0.0019368305802345276], "changes": {"1wk": 1.5829871753021565, "1mo": -13.681598563424041}}, {"text": "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 ACCESS Newswire \u00b7 Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. Thu, Nov 7, 2024, 12:05 AM 18 min read In This Article: AMPH -4.24% Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (\"Amphastar\" or the \"Company\") today reported results for the three months ended September 30, 2024. Third quarter Highlights Net revenues of $191.2 million for the third quarter GAAP net income of $40.4 million, or $0.78 per share, for the third quarter Adjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: \"Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI \u00ae , which has become a cornerstone in our portfolio, and Primatene MIST \u00ae , which is trending toward our goal of $100 million in sales per year. Looking forward, we will focus on positioning our Company towards sustainable, long-term growth by pivoting to high-value and high-growth areas, particularly centered on developing proprietary products and biosimilars, which we expect will allow us to leverage our R&D expertise and technology.\" Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 (in thousands, except per share data) Net revenues $ 191,214 $ 180,556 $ 545,444 $ 466,290 GAAP net income $ 40,429 $ 49,222 $ 121,555 $ 101,378 Adjusted non-GAAP net income* $ 49,585 $ 61,898 $ 153,569 $ 128,823 GAAP diluted EPS $ 0.78 $ 0.91 $ 2.32 $ 1.91 Adjusted non-GAAP diluted EPS* $ 0.96 $ 1.15 $ 2.94 $ 2.43 ____________________________________ * Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled \"Non-GAAP Financial Measures\" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release. Third quarter Results Three Months Ended September 30, Change 2024 2023 Dollars % (in thousands) Product revenues: BAQSIMI \u00ae $ 40,409 $ - $ 40,409 N/A Glucagon 26,792 29,514 (2,722 ) (9 )% Primatene MIST \u00ae 26,055 24,834 1,221 5 % Epinephrine 21,341 20,199 1,142 6 % Lidocaine 15,884 15,522 362 2 % Phytonadione 11,721 7,449 4,272 57 % Enoxaparin 5,615 7,702 (2,087 ) (27 )% Naloxone 4,037 4,715 (678 ) (14 )% Other finished pharmaceutical products 35,503 37,730 (2,227 ) (6 )% Total finished pharmaceutical products net revenues $ 187,357 $ 147,665 $ 39,692 27 % API 1,462 4,190 (2,728 ) (65 )% Other revenues 2,395 28,701 (26,306 ) (92 )% Total net revenues $ 191,214 $ 180,556 $ 10,658 6 % Changes in product revenues as compared to the third quarter of the prior year were primarily driven by: Story Continues BAQSIMI \u00ae revenues consisting of $40.4 million in sales made by the Company directly to its customers, which are recorded as part of product revenues, net, and $6.4 million in sales made by Eli Lilly & Company, or Lilly, on behalf of the Company under a Transition Services Agreement, or TSA, which resulted in a net payment to the Company of $2.4 million after deducting the cost of sales and other expenses and was recorded in other revenues Glucagon sales decreased due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMI \u00ae , as well as a decrease in average selling price Primatene MIST \u00ae sales increased primarily due to an increase in unit volumes Epinephrine sales increased primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter The increase in sales of phytonadione was primarily due to an increase in unit volume, as a result of an increase in demand during the quarter Enoxaparin and naloxone sales decreased primarily due to a decrease in unit volumes Other finished pharmaceutical product sales changes were primarily due to: Lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels These decreases were partially offset by: Higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited The launch of albuterol in August 2024 Between $2.0 million and $4.0 million in sales expected to be recognized in the third quarter were not recognized due to delayed shipments caused by the aftermath of Hurricane Helene. Revenues for these shipments are expected to be recognized in the fourth quarter. Three Months Ended September 30, Change 2024 2023 Dollars % (in thousands) Net revenues $ 191,214 $ 180,556 $ 10,658 6 % Cost of revenues 89,273 72,153 17,120 24 % Gross profit $ 101,941 $ 108,403 $ (6,462 ) (6 )% as % of net revenues 53.3% 60.0% Changes in the cost of revenues and gross margin were primarily driven by: Increased labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value Decrease in other revenues related to Lilly's sales of BAQSIMI \u00ae under the TSA, which are recorded net of cost of sales and other expenses as we assumed distribution of BAQSIMI \u00ae to our customers and are now recording those sales in product revenues and cost of sales separately This was partially offset by: Increase in sales of Primatene MIST \u00ae and epinephrine, which are higher-margin products Three Months Ended September 30, Change 2024 2023 Dollars % (in thousands) Selling, distribution, and marketing $ 8,995 $ 6,407 $ 2,588 40 % General and administrative 14,821 12,654 2,167 17 % Research and development 21,077 16,664 4,413 26 % Selling, distribution, and marketing expenses increased primarily due to the expenses related to the expansion of our sales and marketing efforts related to BAQSIMI \u00ae General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI \u00ae Research and development expenses increased due to expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses, which was partially offset by a decrease in clinical trial expenses due to the timing of clinical trials Three Months Ended September 30, Change 2024 2023 Dollars % (in thousands) Non-operating income (expenses) Interest income $ 2,427 $ 1,202 $ 1,225 102 % Interest expense (6,698 ) (13,702 ) 7,004 (51 )% Other income (expenses), net (5,094 ) 3,459 (8,553 ) (247 )% Total non-operating income (expenses), net $ (9,365 ) $ (9,041 ) $ (324 ) 4 % The change in non-operating income (expenses), net is primarily a result of: An increase in interest income resulting from an increase in cash and investments A decrease in interest expense was primarily due to the $250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of unamortized debt issuance costs related to the Term Loan in 2023 A change to other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts Cash flow provided by operating activities for the nine months ended September 30, 2024, was $184.4 million. Share Buyback Program On November 4, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs. Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions. Pipeline Information The Company currently has four abbreviated new drug applications (\"ANDAs\") on file with the U.S. Food and Drug Administration (the \"FDA\") targeting products with a market size of over $2.4 billion, four biosimilar products in development targeting products with a market size of over $8 billion, and three generic products in development targeting products with a market size of approximately $2 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2024. The Company is developing multiple proprietary products with injectable and intranasal dosage forms. Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. (\"ANP\"), currently has multiple Drug Master Files (\"DMFs\") on file with the FDA and is developing several additional DMFs. Company Information Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com . Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar \u00ae , BAQSIMI \u00ae , Primatene MIST \u00ae , REXTOVY TM , Amphadase \u00ae , and Cortrosyn \u00ae , are the property of Amphastar. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (\"GAAP\"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI \u00ae , certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Conference Call Information The Company will hold a conference call to discuss its financial results today, November 6, 2024, at 2:00 p.m. Pacific Time. To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website at www.amphastar.com . Forward-Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI \u00ae , including its potential for continued revenue growth, the success of our integration of BAQSIMI \u00ae , the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as \"may,\" \"might,\" \"will,\" \"could,\" \"would,\" \"should,\" \"anticipate,\" \"predict,\" \"potential,\" \"continue,\" \"expect,\" \"intend,\" \"plan,\" \"project,\" \"believe,\" \"estimate,\" and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST \u00ae or that we will continue to experience significant sales of BAQSIMI \u00ae . You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 476-3416 Table I Amphastar Pharmaceuticals, Inc. Condensed Consolidated Statement of Operations (Unaudited; in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Net revenues: Product revenues, net $ 188,819 $ 151,855 $ 525,836 $ 437,589 Other revenues 2,395 28,701 19,608 28,701 Total net revenues 191,214 180,556 545,444 466,290 Cost of revenues 89,273 72,153 258,237 211,309 Gross profit 101,941 108,403 287,207 254,981 Operating expenses: Selling, distribution, and marketing 8,995 6,407 27,378 20,234 General and administrative 14,821 12,654 43,782 38,418 Research and development 21,077 16,664 55,772 53,322 Total operating expenses 44,893 35,725 126,932 111,974 Income from operations 57,048 72,678 160,275 143,007 Non-operating income (expenses): Interest income 2,427 1,202 8,320 3,156 Interest expense (6,698 ) (13,702 ) (23,918 ) (17,702 ) Other income (expenses), net (5,094 ) 3,459 1,125 1,553 Total non-operating income (expenses), net (9,365 ) (9,041 ) (14,473 ) (12,993 ) Income before income taxes 47,683 63,637 145,802 130,014 Income tax provision 7,254 14,025 23,674 27,160 Net income before equity in losses of unconsolidated affiliate 40,429 49,612 122,128 102,854 Equity in losses of unconsolidated affiliate - (390 ) (573 ) (1,476 ) Net income $ 40,429 $ 49,222 $ 121,555 $ 101,378 Net income per share: Basic $ 0.83 $ 1.01 $ 2.50 $ 2.10 Diluted $ 0.78 $ 0.91 $ 2.32 $ 1.91 Weighted-average shares used to compute net income per share: Basic 48,621 48,701 48,580 48,368 Diluted 51,862 53,921 52,307 52,997 Table II Amphastar Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (Unaudited; in thousands, except share data) September 30, December 31, 2024 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 192,116 $ 144,296 Restricted cash 235 235 Short-term investments 58,375 112,510 Restricted short-term investments 2,200 2,200 Accounts receivable, net 139,635 114,943 Inventories 130,316 105,833 Income tax refunds and deposits 5,349 526 Prepaid expenses and other assets 17,723 9,057 Total current assets 545,949 489,600 Property, plant, and equipment, net 295,384 282,746 Finance lease right-of-use assets 426 564 Operating lease right-of-use assets 31,708 32,333 Investment in unconsolidated affiliate - 527 Goodwill and intangible assets, net 594,796 613,295 Long-term investments - 14,685 Other assets 23,663 25,910 Deferred tax assets 53,252 53,252 Total assets $ 1,545,178 $ 1,512,912 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities $ 153,268 $ 93,366 Accrued payments for BAQSIMI \u00ae - 126,090 Income taxes payable 1,281 1,609 Current portion of long-term debt 252 436 Current portion of operating lease liabilities 4,209 3,906 Total current liabilities 159,010 225,407 Long-term reserve for income tax liabilities 6,066 6,066 Long-term debt, net of current portion and unamortized debt issuance costs 596,446 589,579 Long-term operating lease liabilities, net of current portion 28,941 29,721 Other long-term liabilities 27,037 22,718 Total liabilities 817,500 873,491 Commitments and contingencies Stockholders' equity: Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding - - Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023 6 6 Additional paid-in capital 496,427 486,056 Retained earnings 530,823 409,268 Accumulated other comprehensive loss (8,821 ) (8,478 ) Treasury stock (290,757 ) (247,431 ) Total equity 727,678 639,421 Total liabilities and stockholders' equity $ 1,545,178 $ 1,512,912 Table III Amphastar Pharmaceuticals, Inc. Reconciliation of Non-GAAP Measures (Unaudited; in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 GAAP net income $ 40,429 $ 49,222 $ 121,555 $ 101,378 Adjusted for: Intangible asset amortization 6,179 6,168 18,539 6,651 Share-based compensation 5,596 4,644 18,736 15,620 Impairment of long-lived assets - 474 - 3,174 Expenses related to BAQSIMI \u00ae acquisition - 2,182 3,651 3,682 Debt issuance costs - 3,019 - 6,043 Income tax provision on pre-tax adjustments (2,619 ) (3,811 ) (8,912 ) (7,725 ) Adjusted non-GAAP net income $ 49,585 $ 61,898 $ 153,569 $ 128,823 Adjusted non-GAAP net income per share: Basic $ 1.02 $ 1.27 $ 3.16 $ 2.66 Diluted $ 0.96 $ 1.15 $ 2.94 $ 2.43 Weighted-average shares used to compute adjusted non-GAAP net income per share: Basic 48,621 48,701 48,580 48,368 Diluted 51,862 53,921 52,307 52,997 Three Months Ended September 30, 2024 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $ 89,273 $ 8,995 $ 14,821 $ 21,077 $ (9,365 ) $ 7,254 Intangible asset amortization (6,159 ) - (1 ) (19 ) - - Share-based compensation (1,133 ) (249 ) (3,710 ) (504 ) - - Income tax provision on pre-tax adjustments - - - - - 2,619 Non-GAAP $ 81,981 $ 8,746 $ 11,110 $ 20,554 $ (9,365 ) $ 9,873 Three Months Ended September 30, 2023 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $ 72,153 $ 6,407 $ 12,654 $ 16,664 $ (9,041 ) $ 14,025 Intangible asset amortization (6,149 ) - 34 (53 ) - - Share-based compensation (1,004 ) (213 ) (2,975 ) (452 ) - - Impairment of long-lived assets (470 ) - (4 ) - - - Expenses related to BAQSIMI \u00ae acquisition - - (357 ) - 1,825 - Debt issuance costs - - - - 3,019 - Income tax provision on pre-tax adjustments - - - - - 3,811 Non-GAAP $ 64,530 $ 6,194 $ 9,352 $ 16,159 $ (4,197 ) $ 17,836 Nine Months Ended September 30, 2024 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $ 258,237 $ 27,378 $ 43,782 $ 55,772 $ (14,473 ) $ 23,674 Intangible asset amortization (18,479 ) - (4 ) (56 ) - - Share-based compensation (4,583 ) (777 ) (11,239 ) (2,137 ) - - Expenses related to BAQSIMI \u00ae acquisition - - - - 3,651 - Income tax provision on pre-tax adjustments - - - - - 8,912 Non-GAAP $ 235,175 $ 26,601 $ 32,539 $ 53,579 $ (10,822 ) $ 32,586 Nine Months Ended September 30, 2023 Selling, General Research Non-operating Cost of distribution and and (expenses) Income revenue and marketing administrative development income, net tax provision GAAP $ 211,309 $ 20,234 $ 38,418 $ 53,322 $ (12,993 ) $ 27,160 Intangible asset amortization (6,582 ) - (16 ) (53 ) - - Share-based compensation (3,868 ) (649 ) (9,323 ) (1,780 ) - - Impairment of long-lived assets (3,170 ) - (4 ) - - - Expenses related to BAQSIMI \u00ae acquisition - - (1,857 ) - 1,825 - Debt issuance costs - - - - 6,043 - Income tax provision on pre-tax adjustments - - - - - 7,725 Non-GAAP $ 197,689 $ 19,585 $ 27,218 $ 51,489 $ (5,125 ) $ 34,885 SOURCE: Amphastar Pharmaceuticals, Inc. View the original press release on accesswire.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-06T21:05:00+00:00", "sentiment": {"score": 0.678934695199132, "confidence": 0.6902211308479309, "probabilities": {"positive": 0.6902211308479309, "negative": 0.011286435648798943, "neutral": 0.2984924614429474}}, "embedding": [-0.04546336084604263, -0.0884900689125061, -0.009957898408174515, -0.08943449705839157, -0.15797767043113708, 0.03622245788574219, -0.009786178357899189, 0.13208067417144775, 0.01799536868929863, 0.1744796633720398, -0.023861490190029144, 0.09211146086454391, 0.053237371146678925, 0.02070077881217003, -0.12116056680679321, 0.07595130801200867, -0.02448529750108719, -9.780935943126678e-05, -0.02516232803463936, 0.0005068471655249596, 0.1101384311914444, 0.05601868778467178, 0.025978371500968933, -0.14057323336601257, 0.1080925390124321, 0.11455398797988892, -0.13425233960151672, 0.034842249006032944, -0.1402670443058014, -0.17079965770244598, 0.008817397058010101, 0.1416850984096527, 0.00249387975782156, -0.03971661999821663, -0.025509005412459373, 0.08017857372760773, -0.09063804149627686, 0.105172298848629, 0.04353797808289528, 0.0016881925985217094, 0.10706533491611481, -0.09607890993356705, -0.12649255990982056, -0.13131414353847504, -0.03801716864109039, -0.18147721886634827, -0.022296370938420296, -0.029890982434153557, 0.053014203906059265, 0.053038690239191055, -0.07611983269453049, -0.08940576761960983, 0.08010467886924744, 0.13825814425945282, -0.028027083724737167, -0.06659354269504547, -0.08950735628604889, -0.03827016055583954, 0.000729030929505825, -0.026447877287864685, -0.0580415353178978, 0.03064507432281971, -0.04767441004514694, -0.07351452857255936, 0.17966309189796448, -0.03233557567000389, -0.023975282907485962, -0.06315240263938904, -0.1347751021385193, 0.03676029294729233, 0.05874983221292496, -0.11351434141397476, -0.12276308238506317, -0.023040002211928368, -0.04415617510676384, 0.12905500829219818, 0.2505241334438324, 0.08893418312072754, 0.15239208936691284, -0.18357905745506287, 0.050903432071208954, 0.10723833739757538, -0.13250507414340973, -0.01652298867702484, -0.07515698671340942, 0.023902051150798798, 0.1049450933933258, 0.08962807059288025, 0.0003849063068628311, -0.11199045181274414, 0.09250551462173462, 0.07367224991321564, 0.027512693777680397, -0.05543942004442215, 0.013401003554463387, -0.07087704539299011, -0.11661060899496078, -0.07815730571746826, 0.09521819651126862, 0.096400186419487, 0.13439640402793884, 0.10684815049171448, -0.14374710619449615, -0.2541769742965698, -0.04148242250084877, -0.16066916286945343, 0.07359375059604645, 0.14276538789272308, -0.025655053555965424, 0.020703740417957306, -0.06338556110858917, 0.08717517554759979, -0.093791164457798, -0.020772092044353485, 0.021449916064739227, 0.15147265791893005, -0.10117915272712708, 0.03143244981765747, 0.1580023467540741, -0.019516658037900925, 0.007461637258529663, 0.09875945001840591, -0.07634908705949783, -0.005785852670669556, -0.06905547529459, 0.0004903813824057579, -0.20754264295101166, 8.53948597540802e-33, -0.00592475850135088, 0.039593715220689774, 0.03345324844121933, -0.15088878571987152, -0.020297007635235786, 0.10487716645002365, 0.04578413441777229, 0.07914755493402481, -0.12096728384494781, -0.05834224075078964, -0.1271756887435913, 0.2278747260570526, -0.026446279138326645, -0.046423062682151794, 0.034803859889507294, -0.14572985470294952, -0.06648188829421997, 0.05590761825442314, 0.02670035883784294, -0.20452824234962463, -0.016917355358600616, -0.10394781827926636, -0.056032925844192505, 0.09586658328771591, 0.0600258968770504, -0.1008903831243515, -0.07537925988435745, 0.05389219895005226, -0.024344800040125847, 0.04760608449578285, 0.07635803520679474, 0.08427203446626663, 0.016275346279144287, -0.21205300092697144, -0.157460555434227, -0.09909997880458832, -0.04150165244936943, -0.08753903210163116, 0.0966968983411789, -0.031318601220846176, -0.1303253173828125, 0.06380954384803772, -0.04399274289608002, -0.056505486369132996, -0.09013970196247101, 0.06420135498046875, 0.04382247477769852, 0.09506455063819885, 0.11610908806324005, 0.048025086522102356, -0.033287063241004944, 0.009338700212538242, 0.030362557619810104, -0.06915262341499329, -0.0820319652557373, 0.09774976968765259, -0.10072541236877441, -0.24679118394851685, 0.06574930995702744, 0.10398778319358826, -0.052870240062475204, 0.0889020562171936, -0.06168082356452942, -0.023891301825642586, -0.2550809383392334, 0.09289471805095673, 0.07722220569849014, 0.07253877818584442, 0.07642179727554321, 0.10138485580682755, -0.03108885884284973, -0.13429445028305054, 0.1142863929271698, -0.11033738404512405, 0.09734595566987991, -0.057008881121873856, 0.0021686768159270287, 0.11173024773597717, 0.0705353245139122, 0.09428444504737854, 0.012195669114589691, 0.03319800645112991, -0.05317758768796921, 0.022750677540898323, -0.04963040351867676, 0.03315802663564682, 0.177537202835083, -0.008038919419050217, -0.06776131689548492, -0.06074167415499687, -0.034717582166194916, -0.03727787733078003, -0.13836225867271423, 0.09301716089248657, -0.09699471294879913, -1.004273900796627e-32, 0.07151161879301071, 0.12100161612033844, -0.04529950022697449, -0.0619046688079834, 0.05046013742685318, -0.05133538693189621, 0.198001891374588, 0.06678888201713562, -0.06747475266456604, -0.017079945653676987, 0.10077168792486191, 0.024247806519269943, 0.01275748573243618, 0.04929662495851517, -0.05468367785215378, -0.00976094976067543, 0.05894933640956879, -0.09527817368507385, 0.050419487059116364, 0.06058762967586517, 0.045974284410476685, 0.2756268382072449, -0.12399063259363174, 0.12191291153430939, -0.026175815612077713, 0.03237222507596016, -0.016013316810131073, 0.08149279654026031, -0.09502233564853668, 0.04414086043834686, -0.07985611259937286, -0.048154041171073914, -0.1773127019405365, -0.04301515966653824, 0.007340359501540661, -0.072760209441185, 0.048663198947906494, -0.1358577162027359, -0.05063164606690407, -0.07446368038654327, 0.13057959079742432, 0.05542468652129173, -0.031534384936094284, 0.05298486724495888, 0.1504625678062439, -0.04841878265142441, 0.10225654393434525, -0.0013305684551596642, 0.025105275213718414, 0.05568000301718712, -0.009285570122301579, 0.0445304773747921, 0.007438186556100845, 0.031094510108232498, -0.11064180731773376, 0.13384994864463806, 0.041804563254117966, 0.0538298562169075, -0.11565518379211426, 0.0022984640672802925, -0.03274303674697876, 0.10371151566505432, 0.03313874825835228, -0.12357769161462784, -0.01333087682723999, 0.04406502842903137, 0.1396210491657257, -0.11002778261899948, 0.10315217077732086, -0.17616873979568481, -0.09585374593734741, -0.08811240643262863, 0.10524139553308487, -0.25080394744873047, -0.10904688388109207, 0.15649142861366272, -0.09846734255552292, -0.03859986364841461, -0.07138189673423767, -0.010057389736175537, -0.029375717043876648, 0.11115777492523193, 0.019122598692774773, 0.06872467696666718, -0.017782527953386307, 0.07289481163024902, -0.026075690984725952, -0.08360853791236877, -0.048408202826976776, 0.08030260354280472, -0.18618953227996826, -0.1425238847732544, -0.058599431067705154, 0.17012794315814972, 0.11196829378604889, -1.0107976322615286e-07, 0.10208197683095932, 0.09282578527927399, 0.03458952531218529, 0.10795193165540695, 0.19260914623737335, -0.08807041496038437, 0.04667646810412407, 0.09105493128299713, 0.09623568505048752, 0.20929256081581116, 0.12235350906848907, 0.031185118481516838, -0.18497711420059204, 0.10473041981458664, -0.06597498804330826, 0.08929133415222168, -0.04905298352241516, 0.08011139929294586, -0.062101006507873535, -0.12892749905586243, -0.05066242441534996, 0.1535986363887787, 0.038811881095170975, 0.028697824105620384, 0.05916633456945419, -0.036378055810928345, -0.03537111356854439, -0.015286166220903397, -0.09912478923797607, 0.03683182969689369, 0.08940830826759338, 0.03611377626657486, 0.028497613966464996, -0.03850368410348892, 0.012094474397599697, -0.11618106812238693, -0.004898888990283012, 0.10466977953910828, 0.030157288536429405, 0.08565398305654526, -0.005659608170390129, 0.0508836954832077, 0.05424554646015167, 0.08137205243110657, -0.022808734327554703, -0.158810555934906, -0.23563888669013977, 0.027988027781248093, 0.0862555131316185, -0.13811984658241272, 0.1477125585079193, -0.05228688567876816, 0.0054381899535655975, -0.08341221511363983, 0.06931836903095245, -0.042444322258234024, -0.1777038723230362, -0.05931418389081955, -0.22611522674560547, 0.1201682984828949, 0.1342368721961975, -0.2871206998825073, 0.041370995342731476, -0.007427085191011429], "changes": {"1wk": -14.831463965041944, "1mo": -17.977531862365158}}, {"text": "Amphastar initiated with an Equal Weight at Wells Fargo TipRanks Sat, Nov 23, 2024, 2:20 PM 1 Minuten Lesezeit In diesem Artikel: AMPH -4.24% https://www.tipranks.com/news/the-fly/zentalis-price-target-lowered-to-10-from-20-at-oppenheimer Wells Fargo initiated coverage of Amphastar ( AMPH ) with an Equal Weight rating and $55 price target The firm likes the setup heading into 2025, saying Amphastar could have 2-3 new launches over the next 12 months, \u201cyet is trading as if there is no pipeline.\u201d Amphastar has a solid commercial business and just a few pipeline wins could drive long-term growth, the analyst tells investors in a research note. Wells sees 20% upside in the shares as the company enters a new product cycle. Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today\u2019s best-performing stocks on TipRanks >> Read More on AMPH: Amphastar Pharmaceuticals Reports Strong Q3 2024 Results AMPH Earnings this Week: How Will it Perform? Kommentare anzeigen AGB und Datenschutzerkl\u00e4rung Privacy Dashboard Empfohlene Nachrichtenartikel", "symbol": "AMPH", "date": "2024-11-23T11:20:42+00:00", "sentiment": {"score": 0.5182235650718212, "confidence": 0.5372782349586487, "probabilities": {"positive": 0.5372782349586487, "negative": 0.01905466988682747, "neutral": 0.44366711378097534}}, "embedding": [-0.2171420305967331, -0.13106797635555267, 0.02388705499470234, 0.06087575480341911, -0.027156393975019455, 0.01824132166802883, 0.06954964995384216, 0.05508112534880638, -0.003328104270622134, 0.07254358381032944, -0.01721971482038498, 0.17329643666744232, -0.032105736434459686, -0.033724162727594376, -0.045734476298093796, 0.06689002364873886, 0.11648911237716675, -0.18079115450382233, -0.15273918211460114, -0.04950007051229477, 0.017049409449100494, -0.20695242285728455, 0.03270081430673599, -0.08590782433748245, 0.13872866332530975, 0.04536466300487518, -0.14933665096759796, 0.04735678806900978, -0.07442521303892136, -0.17622950673103333, -0.024948829784989357, 0.022085344418883324, -0.010813514702022076, -0.16480368375778198, -0.06371574103832245, 0.06922627240419388, -0.04694952443242073, 0.0289828609675169, 0.13127586245536804, 0.06853190064430237, 0.04028370603919029, -0.1316290646791458, -0.22758573293685913, -0.08672316372394562, -0.04514886066317558, -0.14281094074249268, 0.013223576359450817, -0.048727065324783325, 0.03170178830623627, 0.05921873450279236, -0.1305650919675827, -0.10114284604787827, 0.10390575975179672, 0.047197986394166946, -0.050395067781209946, 0.059930749237537384, -0.0873694121837616, 0.01628264971077442, 0.09585662931203842, -0.08801566809415817, 0.013068104162812233, -0.06565381586551666, 0.050772953778505325, -0.04186218976974487, 0.09108977764844894, -0.05936344712972641, -0.02386031299829483, -0.029080741107463837, -0.025876550003886223, -0.008836773224174976, 0.08638453483581543, -0.012606509029865265, -0.055452678352594376, -0.00860100518912077, 0.0036921368446201086, 0.14251968264579773, 0.15517768263816833, -0.08387666940689087, 0.11174323409795761, -0.04094919562339783, -0.0385424830019474, -0.01571476459503174, -0.1278674602508545, -0.04479222744703293, -0.0541190579533577, 0.004657703917473555, 0.09005216509103775, 0.02565685287117958, 0.06882970780134201, -0.029215913265943527, 0.05519353970885277, -0.012371317483484745, -0.08914127200841904, -0.016811706125736237, 0.10716847330331802, 0.021952606737613678, -0.22148941457271576, -0.05663115903735161, -0.033816125243902206, 0.07619522511959076, 0.16777712106704712, 0.08896730840206146, -0.03207182139158249, -0.1282050758600235, 0.017504343762993813, -0.13489364087581635, 0.011908596381545067, 0.10494527220726013, -0.006044160109013319, -0.05866526439785957, 0.08089417964220047, 0.061399929225444794, 0.11042948812246323, 0.03928813710808754, -0.1124970093369484, 0.11030970513820648, -0.06901435554027557, 0.034163810312747955, 0.055560048669576645, 0.06596910208463669, 0.04994206875562668, 0.04902663826942444, -0.009916682727634907, -0.03833991289138794, -0.06506488472223282, 0.21966879069805145, -0.21880322694778442, 1.5248511249498775e-32, 0.03540579602122307, 0.09783098846673965, -0.03077489696443081, -0.12687742710113525, 0.00026616992545314133, -0.012053219601511955, -0.0030107886996120214, 0.07474491745233536, -0.22176937758922577, -0.06250160187482834, -0.06977900117635727, 0.07654999941587448, -0.017523949965834618, 0.0376448854804039, -0.1129445806145668, -0.12241494655609131, -0.027964726090431213, 0.05997946858406067, -0.013557982631027699, -0.13789701461791992, 0.08537382632493973, -0.10964834690093994, -0.13908299803733826, -0.0912429690361023, 0.052968014031648636, -0.07665545493364334, 0.04058077558875084, 0.042834311723709106, -0.09943241626024246, 0.08492721617221832, -0.00861689168959856, 0.049325570464134216, -0.07405243068933487, -0.13399673998355865, 0.0021473527885973454, -0.08808812499046326, -0.06441652029752731, -0.08038564771413803, -0.0545642226934433, -0.12397130578756332, -0.08265288919210434, 0.10831695050001144, -0.10533538460731506, 0.01937047205865383, -0.007548128254711628, 0.06459666043519974, -0.028020303696393967, 0.029153352603316307, 0.10085521638393402, 0.01108285877853632, -0.10798852145671844, -0.025069495663046837, 0.012136275880038738, 0.03940533474087715, -0.07639078050851822, 0.08738084137439728, 0.01182275265455246, -0.1404455155134201, 0.09639275819063187, 0.07796809077262878, -0.03256597742438316, 0.15718939900398254, -0.13877467811107635, -0.07169777154922485, -0.20431602001190186, 0.10373041033744812, 0.10212760418653488, 0.06186223402619362, -0.036382321268320084, 0.138270765542984, 0.12436790019273758, -0.03610707074403763, 0.08201398700475693, 0.013769049197435379, 0.11097556352615356, -0.022439371794462204, 0.05945752188563347, 0.04416275396943092, 0.11030936241149902, -0.00045369763392955065, 0.058078207075595856, -0.030560482293367386, 0.08232886344194412, -0.03591481223702431, -0.06327208876609802, -0.0446036159992218, 0.08204115182161331, -0.1006927490234375, -0.09608475863933563, -0.009380608797073364, -0.009049126878380775, 0.08635126054286957, -0.09556997567415237, 0.05615821108222008, -0.11846275627613068, -1.3022445271251962e-32, 0.021712688729166985, 0.0007307075429707766, -0.045023225247859955, 0.07423443347215652, 0.04840608313679695, 0.03453356772661209, 0.07871654629707336, 0.03895794600248337, -0.013235936872661114, -0.03262292593717575, 0.0473298616707325, 0.0975477397441864, -0.08971007168292999, 0.0528700090944767, 0.06194749474525452, -0.07387229055166245, -0.0012919780565425754, -0.12874653935432434, 0.09181790053844452, 0.02675429917871952, 0.017810875549912453, 0.10036369413137436, -0.20713043212890625, 0.2889547646045685, 0.08982717245817184, 0.04697033762931824, -0.01967308670282364, 0.11401134729385376, -0.12138180434703827, 0.014934057369828224, -0.05956637114286423, -0.02906615100800991, -0.07760664820671082, 0.03268921375274658, -0.05110364779829979, 0.03288274258375168, 0.07863148301839828, -0.03282398730516434, -0.03152443841099739, 0.060461439192295074, 0.08857670426368713, -0.005834431387484074, 0.12031203508377075, -0.03417576849460602, -0.037531763315200806, -0.0006897742277942598, 0.06072495877742767, 0.008904462680220604, -0.05395786836743355, 0.02852647937834263, -0.019590461626648903, 0.05445943400263786, 0.005978197790682316, 0.20425166189670563, -0.07092595100402832, 0.024634094908833504, -0.017740055918693542, 0.12080775946378708, -0.1834336817264557, 0.048182155936956406, 0.0024584962520748377, 0.12304872274398804, 0.10732909291982651, -0.0034847173374146223, -0.0026091323234140873, -0.054335031658411026, 0.1031259149312973, -0.08775089681148529, 0.0343540795147419, -0.09423831850290298, -0.04013726860284805, -0.10129314661026001, 0.1280750185251236, -0.14884717762470245, -0.10205332189798355, 0.10281486064195633, -0.017801832407712936, -0.057442981749773026, -0.04539880529046059, -0.036182988435029984, -0.02897467650473118, 0.06165122240781784, 0.0025060607586055994, 0.056745897978544235, 0.049154412001371384, 0.15002644062042236, 0.03860403969883919, -0.003882118035107851, 0.007267692591995001, 0.10226478427648544, -0.10824673622846603, -0.11675438284873962, -0.10899939388036728, 0.11744266748428345, 0.056419502943754196, -1.0000799477438704e-07, 0.06163768842816353, 0.05151684209704399, 0.0077511961571872234, 0.10944800823926926, 0.1246066465973854, -0.07698943465948105, 0.08129693567752838, 0.08089382946491241, -0.0033264413941651583, 0.1611466258764267, 0.14214058220386505, 0.027698568999767303, -0.13294079899787903, 0.048847950994968414, -0.025866979733109474, -0.06255088746547699, -0.008583737537264824, 0.11299236863851547, -0.06295499205589294, -0.07949774712324142, 0.06136578321456909, 0.15544281899929047, 0.08479674905538559, -0.008803383447229862, 0.07316108793020248, -0.007725045550614595, 0.043515559285879135, -0.0261662807315588, 0.02000218629837036, 0.01713825762271881, -0.062272991985082626, 0.04079050570726395, -0.0022281925193965435, -0.05975540727376938, 0.0738278478384018, 0.11410950124263763, -0.05138525739312172, 0.03339265286922455, -0.04264770820736885, 0.1393273025751114, 0.009010904468595982, 0.05556408315896988, 0.0376434251666069, -0.060541585087776184, -0.0025759804993867874, -0.08694939315319061, -0.1663944572210312, -0.04307027533650398, 0.0776044949889183, -0.02781950682401657, 0.13075223565101624, -0.08140898495912552, -0.0310511477291584, 0.07439494132995605, 0.05339629948139191, 0.011021899990737438, -0.17164212465286255, -0.0654577687382698, -0.12670433521270752, 0.08486901968717575, 0.21547500789165497, -0.20938946306705475, 0.005891126114875078, 0.08252760022878647], "changes": {"1wk": 1.232077160798721, "1mo": -12.320788698925014}}, {"text": "Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings Call Highlights: Resilient Revenue Growth ... GuruFocus News Thu, Nov 7, 2024, 10:24 AM 4 min read In This Article: AMPH -4.24% Net Revenue: $191.2 million, a 6% increase year over year. Primatene Mist Sales: $26 million, highest quarterly sales since launch. Glucagon Sales: $26.7 million, a 9% decline from the previous year. Vaccine Sales: $40.4 million through Amphastar, $6.4 million by Eli Lilly. Epinephrine Sales: $21.3 million, a 6% increase. Phytonadione Sales: $11.7 million, a 57% increase. Gross Margin: Declined to 53% from 60% in the prior year. Net Income: $40.4 million, an 18% decrease from the previous year. Adjusted Net Income: $49.6 million, compared to $61.9 million in the previous year. Cash Flow from Operations: Approximately $60 million. Share Repurchase: $35 million used to repurchase 797,000 shares. New Buyback Program: Authorized an additional $50 million. Warning! GuruFocus has detected 3 Warning Signs with AMPH. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) reported a 6% increase in net revenues year over year, reaching $191.2 million, demonstrating resilience and growth in their diversified product portfolio. Primatene Mist achieved its highest quarterly sales since launch, reaching $26 million, marking significant progress towards the company's goal of $100 million in annual sales by the end of 2024. The launch of the Albuterol MDI product in the third quarter of 2024 expanded Amphastar's respiratory portfolio, positioning the company to meet growing demand for affordable asthma management options. The company announced the introduction of AMP 028, a new biosimilar addition to their pipeline, which has potential sales of over $2 billion, marking a strategic shift towards high-value therapeutic areas. Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) continues to advance its diabetes portfolio, with plans to refile their BLA for insulin aspart in the fourth quarter and their GLP-1 NDA AMP 018 receiving priority review. Negative Points Hurricane Helane impacted logistics, resulting in delayed shipments and negatively affecting sales by $2 to $4 million in the third quarter. Glucagon sales decreased by 9% to $26.8 million due to increased competition in the market, reflecting a decline in unit shipments. Gross margins declined to 53% from 60% in the prior year, primarily due to changes in the distribution of vaccine sales and increased labor and component costs. Selling, distribution, and marketing expenses increased by 40% due to the expansion of the vaccine sales force, impacting overall profitability. Net income decreased by 18% to $40.4 million, or 78 cents per share, compared to the previous year, with adjusted net income also showing a decline. Story Continues Q & A Highlights Q : Can you provide any updates on the competitive dynamics and peak sales potential for your products, particularly in the GLP-1 category? A : William Peters, CFO, stated that the transition of vaccine distribution is going smoothly despite a temporary supply disruption in Europe. The company remains on target for peak sales of $250 to $275 million. Regarding the GLP-1 category, Dan Dischner, VP of Corporate Communications, mentioned that it's a crowded market, and while it's too early to discuss specifics, updates will be provided as they become available. Q : What were the main drivers of lower revenue for Epinephrine, and how do you plan to offset this? A : William Peters explained that the decrease in Epinephrine revenue was due to competition in the multi-dose vial market, partially offset by increased sales of prefilled syringes in Canada. The company plans to expand its sales force to drive growth in other areas, such as vaccine, to offset fluctuations in the base business. Q : Can you discuss the sales potential for the generic Albuterol HFA and any updates on AMP 002 and AMP 007? A : William Peters noted that Albuterol HFA is expected to be a meaningful product in 2025, with a gradual market share increase. Dan Dischner mentioned ongoing discussions with the FDA for AMP 002, with potential progress soon. For AMP 007, the FDA extended the action date, but there are no alarming issues, and the company remains optimistic. Q : What are the competitive headwinds affecting vaccine sales, and what is the plan for sales force investment? A : William Peters attributed the year-over-year decline in vaccine sales to temporary supply disruptions in Europe and pricing adjustments in the U.S. The company plans a significant sales force expansion in January, with some related expenses in the fourth quarter, utilizing an outsourced model for flexibility. Q : Can you clarify the nature of AMP 007 as a combination product and its competitive landscape? A : William Peters clarified that AMP 007 is a drug-device combination product, similar to other inhalation products. The company has not disclosed specific competition details for this product at this time. For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AMPH", "date": "2024-11-07T07:24:33+00:00", "sentiment": {"score": 0.9251856338232756, "confidence": 0.9499673843383789, "probabilities": {"positive": 0.9499673843383789, "negative": 0.02478175051510334, "neutral": 0.02525092475116253}}, "embedding": [-0.030705498531460762, -0.11498481035232544, 0.02135544642806053, -0.09249739348888397, -0.10225783288478851, 0.03133131563663483, 0.054753564298152924, 0.16398508846759796, 0.07626911252737045, 0.1482713520526886, 0.003233077935874462, 0.06708674132823944, 0.083102285861969, -0.010427117347717285, -0.053367286920547485, 0.0869629830121994, 0.05212683230638504, -0.05507268011569977, -0.1241316944360733, -0.04708094149827957, 0.09827280044555664, 0.03659532964229584, 0.05204401910305023, -0.06432481110095978, 0.09014871716499329, 0.054135896265506744, -0.16456663608551025, 0.013201425783336163, -0.13900622725486755, -0.18792077898979187, 0.022920506075024605, 0.054772526025772095, 0.0565548911690712, -0.06401895731687546, -0.08055250346660614, 0.025456994771957397, -0.09059233963489532, 0.06178826466202736, 0.0048552947118878365, 0.035746749490499496, 0.07847730815410614, -0.05100732296705246, -0.19317716360092163, -0.112336166203022, -0.03294464573264122, -0.14968445897102356, -0.04501241445541382, 0.04092942550778389, 0.10058076679706573, 0.1094207614660263, -0.050549402832984924, -0.15912652015686035, 0.06538821011781693, 0.08547388017177582, -0.08684484660625458, -0.011897925287485123, -0.1999087631702423, 0.04581229016184807, 0.01071089692413807, -0.021356990560889244, -0.049115944653749466, -0.021128999069333076, -0.010280761867761612, -0.05251743644475937, 0.09760123491287231, -0.0320754311978817, 0.0022848574444651604, -0.06437662243843079, -0.05155312269926071, -0.008660292252898216, 0.07664721459150314, -0.046255581080913544, -0.024651309475302696, 0.02576257847249508, -0.04712056368589401, 0.13290119171142578, 0.15822456777095795, 0.02060287445783615, 0.08280625939369202, -0.05634099990129471, 0.09959855675697327, 0.06551584601402283, -0.11573676764965057, 0.01416315883398056, 0.01664848066866398, 0.006321393884718418, 0.09486496448516846, 0.13507436215877533, 0.01805681735277176, -0.0886860340833664, 0.08381645381450653, 0.030815254896879196, 0.00217233644798398, -0.015828892588615417, -0.02861306257545948, -0.033695027232170105, -0.14632534980773926, -0.017664115875959396, 0.06529412418603897, 0.08221960067749023, 0.05459092929959297, 0.06595905870199203, -0.08608721196651459, -0.23592981696128845, 0.011836269870400429, -0.1416710913181305, 0.09789490699768066, 0.09478916227817535, -0.010420165956020355, -0.005259748548269272, -0.06393679231405258, 0.0674988180398941, -0.03858981281518936, 0.011371646076440811, -0.07044807076454163, 0.272891104221344, -0.0632396787405014, 0.022924795746803284, 0.06058843433856964, -0.09444475173950195, 0.06811544299125671, -0.028218664228916168, 0.01957133784890175, -0.01673814281821251, -0.053833529353141785, 0.05261710286140442, -0.1379440426826477, 1.1923431521630049e-32, 0.019673801958560944, 0.0706082433462143, 0.06820438802242279, -0.13893768191337585, 0.02360491454601288, 0.08272230625152588, 0.002612549811601639, 0.07267299294471741, -0.060276903212070465, -0.09825734794139862, -0.19753000140190125, 0.09851829707622528, -0.03776119649410248, 0.07580897212028503, -0.06186265870928764, -0.13944895565509796, -0.05745895579457283, 0.09413988888263702, 0.03671449422836304, -0.14125540852546692, -0.08671979606151581, -0.05292949825525284, -0.09674418717622757, 0.12024302780628204, -0.04168214648962021, 0.02543680928647518, -0.029474880546331406, 0.11212758719921112, 0.036348700523376465, 0.038342077285051346, 0.0085208835080266, 0.04989348724484444, -0.014027807861566544, -0.15284578502178192, -0.13298672437667847, -0.11113495379686356, -0.0448821559548378, -0.14062240719795227, 0.13238346576690674, 0.014063578099012375, -0.10164683312177658, 0.14325180649757385, -0.0726921558380127, -0.09319479763507843, -0.05823604762554169, 0.021760819479823112, -0.06813570111989975, 0.004593279678374529, 0.05037277191877365, 0.07562276721000671, -0.05792103707790375, 0.03353717923164368, 0.03841640055179596, 0.03203504532575607, -0.11031006276607513, 0.041187822818756104, -0.10297960042953491, -0.10979044437408447, 0.07610498368740082, 0.17766708135604858, -0.038771722465753555, 0.1404808759689331, 0.0023048706352710724, -0.01773158274590969, -0.2020716518163681, 0.11123303323984146, 0.05074305087327957, -0.009420996531844139, -0.0014991648495197296, 0.17428354918956757, 0.03947391360998154, -0.0527225024998188, 0.08133161067962646, -0.10488271713256836, 0.1486944556236267, -0.09145324677228928, 0.0061155641451478004, 0.06548731029033661, 0.020567039027810097, 0.06926505267620087, 0.027143986895680428, 0.00748808030039072, -0.035089801996946335, 0.08348531275987625, -0.0689920037984848, 0.04643220081925392, 0.07618247717618942, -0.005276065785437822, -0.04541846364736557, -0.06848447769880295, -0.006902484223246574, 0.011873090639710426, -0.08908575773239136, 0.05413377285003662, -0.02094501629471779, -1.0294112597417863e-32, 0.05599439889192581, 0.060384951531887054, 0.006758558098226786, -0.025907758623361588, 0.07308892905712128, 0.034850362688302994, 0.15200087428092957, 0.059618670493364334, -0.03206394240260124, -0.028982367366552353, 0.04866521805524826, 0.0902327373623848, -0.024036183953285217, 0.017194963991642, 0.014155011624097824, 0.01665612682700157, -0.005183681845664978, -0.10334762930870056, 0.06430482864379883, -0.01065119169652462, 0.019308581948280334, 0.24310490489006042, -0.02478215843439102, 0.15105003118515015, 0.043879490345716476, 0.004656022880226374, -0.023004276677966118, 0.11949518322944641, 0.05300598964095116, -0.02378349006175995, -0.03344286233186722, 0.032686952501535416, -0.19202548265457153, 0.004677208606153727, 0.022280147299170494, -0.07251384854316711, 0.04709628224372864, -0.16413496434688568, -0.002666860818862915, -0.0847148597240448, 0.09414469450712204, -0.012045558542013168, 0.03977026045322418, 0.0015156250447034836, 0.13083231449127197, -0.04868129640817642, 0.10376136004924774, -0.03854843229055405, 0.06545098125934601, 0.04651812091469765, -0.039254914969205856, 0.03704545274376869, -0.014236542396247387, 0.04847847670316696, -0.0761362612247467, 0.06774059683084488, 0.01810811460018158, 0.050948284566402435, -0.10862278938293457, -0.014769582077860832, -0.050380028784275055, 0.054461024701595306, -0.027595853433012962, -0.0877765491604805, -0.04549768939614296, 0.038524921983480453, 0.1337490975856781, -0.08064156770706177, 0.11973799020051956, -0.12876909971237183, -0.013307308778166771, -0.11765903234481812, 0.09740516543388367, -0.1585155576467514, -0.1477033793926239, 0.08809849619865417, -0.07602506875991821, -0.07912107557058334, -0.07129373401403427, -0.07920514792203903, 0.042727552354335785, 0.08925574272871017, 0.07163982838392258, -0.017471369355916977, 0.035683464258909225, 0.1087772399187088, -0.02568061649799347, -0.00724049611017108, -0.06769858300685883, 0.18601691722869873, -0.16996294260025024, -0.12477542459964752, -0.10893495380878448, 0.16859343647956848, 0.07605180889368057, -1.0060772837050536e-07, 0.1432172954082489, 0.06565937399864197, 0.06892108917236328, 0.10686077177524567, 0.1426282674074173, -0.07390295714139938, 0.031759824603796005, 0.13185100257396698, 0.04535204917192459, 0.1840732991695404, 0.07206227630376816, 0.04318060725927353, -0.17682623863220215, 0.055767323821783066, -0.05555710941553116, 0.08381050825119019, -0.03805889934301376, 0.0929674357175827, -0.03454458341002464, -0.05623634159564972, -0.06608538329601288, 0.10321386903524399, -0.04498734325170517, -0.05319001525640488, 0.010343296453356743, -0.029587797820568085, 0.024946648627519608, 0.02594779059290886, -0.07863331586122513, -0.03055296652019024, 0.07857555150985718, 0.013327071443200111, 0.02941388450562954, 0.01577732339501381, 0.020603066310286522, -0.090359628200531, -0.020477166399359703, 0.08794540911912918, 0.0036765392869710922, 0.05992279201745987, -0.03670073300600052, 0.006491709500551224, 0.03926943242549896, 0.023761030286550522, -0.06217995285987854, -0.11528247594833374, -0.13600626587867737, -0.06628970801830292, 0.06591133028268814, -0.08057771623134613, 0.14036497473716736, -0.051643941551446915, 0.008099565282464027, -0.12188684940338135, -0.0546063557267189, -0.017149843275547028, -0.2277102768421173, -0.09946684539318085, -0.08964930474758148, 0.0159746203571558, 0.13490815460681915, -0.2554483115673065, 0.08802928030490875, 0.02955026365816593], "changes": {"1wk": -1.3234988247603896, "1mo": -4.968541783349861}}]